0.60%, N=3
0.90%, N=5
0.011 µM,0.005 to 0.110 µM
1 mCi,1 mL and each milliliter contains 37 MBq
1 mg/kg/min,1000 mcg/kg/min
1 mg/mL,10 mg/10 mL vial
1 mg/mL,1 mg of donepezil hydrochloride in each mL
1&#160;unit,"valign=""top"">9-17&#160;minutes</td>                               </tr>                               <tr>                                  <td align=""left"" valign=""top"">1-mg"
1.0 g/d,1; and 500 mg twice daily
10 mg/kg/min,10
140-age,(140-age)(weight)/[(72)(Sfor males C cr =
140-age,(140-age)(weight)/[(72)(Sfor males Ccr =
140-age,(140-age)(weight)/[(72)(SCr)]                   for males CCr =
15 mg/min,150 mg over the FIRST 10 minutes
17.7 mA-min,1.77 mA for 10 minutes
1-PP,1-pyrimidinylpiperazine
2 ?g/kg,2 micrograms per kilogram
2 mg/mL,10139-061-25200 mg/100 mL
2 mg/mL,follows:200 mg/100 mL
2.5 mg/kg/min,2500 mcg/kg/min
2.5 mg/mL,25 mg/10 mL
20 mg/mL,200 mg of panitumumab in 10 mL
25 mg,"valign=""top""><paragraph>250 mL</paragraph></td><td valign=""top""><paragraph>5 mL"
2'5'OAS,2'5' oligoadenylate synthetase
29 minutes,29 minutes and were consistent with the t½? of cisatracurium in vitro
2F-ara-A,2-fluoro-ara-adenine
2F-ara-ATP,2-fluoro-ara-ATP
2PY,N-methyl-2-pyridone-5-carboxamide
3 mg/kg/min,3000 mcg/kg/min
3HQ,3–hydroxy–quinidine
4PY,N-methyl-4-pyridone-5-carboxamide
5 g,500 mg  Tablets
5 mL,0.5 gm sulfisoxazole per teaspoonful
50 mg,"valign=""top""><paragraph>500 mL</paragraph></td><td valign=""top""><paragraph>10 mL"
5-ASA,5-aminosalicylic acid
5-FU,5-fluorouracil
5HIAA,5-hydroxy indoleacetic acid
5HIAA,5-hydroxy indoleacetic  acid
5HIAA,5-hydroxyindoleacetic acid
5-HIAA,5-hydroxyindoleacetic acid
5-HIAA,5-hydroxyindole acetic acid
5-HIAA,5?hydroxyindoleacetic acid
5-HMT,5-hydroxymethyl tolterodine
5-HT,5-hydroxytryptamine
5-HT1B/1D,5-hydroxytryptamine1B/1D
5-HT3,5-hydroxytryptamine3
6mg/mL,6 mg/mL for intravenous use.NDC 67286-0054-2            10mL
6MNA,6- methoxy-2-naphthylacetic acid
6-MP,6-mercaptopurine
6-TGNs,6-thioguanine nucleotides
7.5 mg/mL,9.75 mg/1.3 mL
95% CI,278.6(51.8)211.9(49)46.9(11.9)90(50.7)186.3(38.1)Simvastatin24 Weeks106% Change from Baseline
95% CI,95% confidence intervals
A®,assay
AA,arachidonic acid
AAG,alpha1 acid glycoprotein
AAG,alpha-1-acid glycoprotein
ABC,Aberrant Behavior Checklist
ABC,Aberrant Behavior  Checklist
ABECB,acute bacterial exacerbation of chronic bronchitis
ABECB,acute bacterial exacerbations of chronic bronchitis
about 1%,about 1.5% of patients and was not significantly different from placebo
about 1%,about 1.5% of patients and was not significantly different                         from placebo
about 1%,about 1.5% of patients and was not significantly  different from placebo
about 1%,about 1.5% of patients and was not  significantly different from placebo
ABPM,ambulatory  blood pressure monitoring
ABPM,ambulatory blood pressure monitoring
ABS,acute bacterial sinusitis
AC,and cyclophosphamide
AC,and                                             cyclophosphamide
AC,and cyclophosphamide 600 mg/m2
AC?TH,AC?T but not to TCH [44%
Ac-5-ASA,N-acetyl-5-ASA
ACAPS,Asymptomatic Carotid Artery Progression Study
ACE,angiotensin converting enzyme
ACE,angiotensin-converting enzyme
ACE,angiotensin  converting enzyme
ACE,angiotensin-coverting enzyme
ACE,angiotensin converting  enzyme
ACE,angiotensin I-converting enzyme
ACE,AspirinAngiotensin Converting Enzyme
ACEI,angiotensin-converting enzyme inhibitor
ACEi,angiotensin converting enzyme inhibitor
acetate,"align=""center"" valign=""top""><paragraph>425</paragraph></td></tr> <tr><td valign=""top""><paragraph>Lysine"
acetate,"align=""center"" valign=""top""><paragraph>850</paragraph></td></tr> <tr><td valign=""top""><paragraph>Lysine"
acetate,"align=""center"" valign=""top""><paragraph>940</paragraph></td></tr> <tr><td valign=""top""><paragraph>Lysine"
ACh,acetylcholine
AChE,Acetylcholinesterase
ACOG,and Gynecologists
AC-PC,anterior commissure-posterior commissure
ACR,American College of Rheumatology
ACS,acute coronary syndrome
ACT,activated clotting time
ACTG,AIDS Clinical Trials Group
ACTH,adrenocorticotropic hormone
AD,Alzheimer's disease
AD,Alzheimer disease
AD,Alzheimer’s disease
ADA,anti-drug antibodies
ADCS-ADL,Alzheimer’s Disease Cooperative Study-Activities of Daily Living
ADCS-CGIC,Alzheimer’s Disease Cooperative Study—Clinicians Global Impression of Change
ADCS-CGIC,Alzheimer’s  Disease Cooperative Study - Clinician’s Global Impression of Change
ADCS-CGIC,Alzheimer’s Disease Cooperative Study – Clinician’s Global  Impression of Change
ADCS-CGIC,Alzheimer’s Disease Cooperative Study – Clinician’s Global Impression of Change
ADCS-CGIC,Alzheimer’s Disease Cooperative Study - Clinician’s Global Impression of Change
ADCS-CGIC,Alzheimer’s Disease Cooperative Study - Clinical Global  Impression of Change
ADCS-CGIC,Alzheimer’s Disease Cooperative Study - Clinical Global Impression of Change
ADH,antidiuretic hormone
ADH,avoid possible contamination with vasopressin
ADHD,Attention-Deficit/Hyperactivity Disorder
ADHD,Attention–Deficit/Hyperactivity Disorder
ADHD,Attention Deficit Hyperactivity Disorder
ADHD,Attention Deficit  Hyperactivity Disorder
ADHD,Attention-Deficit Hyperactivity Disorder
ADHD,Attention-Deficit/ Hyperactivity Disorder
ADHDRS,ADHD Rating Scale-IV-Parent Version
ADHD-RS,Attention Deficit Hyperactivity Disorder-Rating Scale
ADHD-RS,Attention Deficit Hyperactivity Disorder-Rating  Scale
ADHF,acute decompensated heart failure
ADL,Activities of Daily Living
ADOPT,AVANDIA as  Monotherapy                                      A 4- to 6-year study
ADOPT,A Diabetes Outcome Progression Trial
ADP,adenosine diphosphate
adrenergic,and nasal passages.Pseudoephedrine: Pseudoephedrine acts as an indirect sympathomimetic agent by stimulating sympathetic
ADRs,adverse drug reactions
ADT®,Alternate Day  Therapy
ADT®,Alternate Day Therapy
adult,and Lethal Doses Butalbital: toxic dose 1 g
adults,accordance with the dosing guidelines in Tables 10
AE,adverse event
AECB,acute exacerbation of chronic bronchitis
AECB,acute  exacerbation of chronic bronchitis
AED,antiepilepsy drug
AED,antiepileptic drug
AED,1 antiepileptic drug
AEDs,Antiepilepsy Drugs
AEDs,antiepileptic drugs
AEs,adverse events
AEs,adverse effects
AF,Atrial Fibrillation
AF,after sotalol hydrochloride tablets
AFIB,atrial fibrillation
AFIB/AFL,atrial fibrillation/atrial flutter
AG,adenine-guanines
AGC,absolute granulocyte count
AHS,Anticonvulsant Hypersensitivity Syndrome
AI,1-aminoindan
AI,Adequate Intake
AIBW,Adjusted ideal body weight
AIDS,Acquired                                                                                                            Immunodeficiency Syndrome
AIDS,Acquired  Immunodeficiency Syndrome
AIDS,acquired immunodeficiency syndrome
AIDS,Acquired Immune Deficiency Syndrome
AIDS,Acquired Immunodeficiency
AIDS,Acquired Immunodeficiency  Syndrome
AIOD,aortoiliac occlusive disease
AK,actinic keratoses
AKs,actinic keratoses
ALA,aminolevulinic acid
ALA,aminolevulinate
ALA,delta-aminolevulinic acid
ALA HCl,aminoketone.Aminolevulinic acid HCl
ALAD,metalloenzyme-?-aminolevulinic acid dehydrase
ALARA,as low as reasonably achievable
ALC,absolute lymphocyte counts
ALFENTA,alfentanil hydrochloride
ALL,acute lymphoid leukemia
ALL,acute lymphoblastic leukemia
ALL,acute lymphocytic leukemia
ALOPRIM,allopurinol sodium
ALT,at baseline <3 times ULN
ALT,alanine aminotransferase
ALT,Abnormalities                                               Increases in serum transaminase
ALT,"align=""left"">&#160;&#160;&#160;&#160;Elevated SGPT"
ALT,"align=""left"" colspan=""1"" rowspan=""1"">SGPT"
ALT,alanine transaminase
ALT,Abnormalities                                                Increases in serum transaminase
ALT,ACEON® Tablets vs 0.9% placebo
ALT,alanine  aminotransferase
ALT,as follows:  Hepatic – elevated SGPT
ALT,alanine                                     transaminase
ALT,alanine treatment transaminase and hemorrhage
ALT,as follows: Hepatic - elevated SGPT
ALT,as follows:Hepatic - elevated SGPT
ALT,<tr><td/><td>&#8593;Alanine aminotransferase
ALT,as follows:                                         Hepatic elevated SGPT
ALT,at  baseline less than 3X ULN
ALT,AbnormalitiesIncreases in serum transaminase
ALT,abnormalities in measures of hepatocellular function
ALT,Abnormalities Increases in serum transaminase
ALT,Abnormalities                                      Increases in serum transaminase
ALT,as follows:                   Hepatic–elevated SGPT
ALT,values-alanine aminotransferase
ALT,values—alanine aminotransferase
ALv,attachment level
AM,and Memory
AM PEF,and morning peak expiratory flow
AMD,Age-Related Macular Degeneration
Ames,assay using human lymphocytes was negative.Salmonella
Ames,a rat micronucleus test.Salmonella
Ames,assays included bacterial mutagenicity tests with Salmonella
Ames,a battery of mutagenicity tests
Ames test,alone in the following in vitro tests: Salmonella microsome test
Ames test,area.Glimepiride was non-mutagenic in a battery ofin vitroandin vivomutagenicity studies
Ames test,administration did not produce chromosome aberrations.in vitro bacterial reverse mutation assay
Ames test,at dietary doses up to 6 mg/kg/day of ipratropium bromide.Results of various mutagenicity studies
Ames test,a mg/mMutagenesis: Citalopram was mutagenic in the in vitro bacterial reverse mutation assay
Amino Acid,amino acids present in the solution.®
Amino Acid,amino acids.®
Amino Acid,amino acids.Adequate                                     calories should be administered simultaneously.Patients                                     receiving RenAmin®
AML,a mixed population of hematological malignancies
AML,Acute Myeloid Leukemia
AML,acute myelogenous leukemia
AML,acute myelogeneous leukemia
AML/MDS,acute myelogenous leukemia or myelodysplastic syndrome
AMPHOTEC®,Amphotericin B
ampicillin,anaerobic bacteria resistant to some penicillin antibiotics
AMS,acute  mountain sickness
AMS,acute mountain sickness
AMT,3?-amino-3?-deoxythymidine
AMT,3'-amino-3'-deoxythymidine
AMT,3’-amino-3’-deoxythymidine
ANA,antinuclear antibodies
ANA,antinuclear antibody
ANA,anti-nuclear antibody
ANC,absolute neutrophil count
ANC,absolute neutrophil counts
Anemia,anemias progressing on therapy
ANF,antinuclear factor
Angioedema,Angiodema and Intestinal Angiodema
ANLL,acute non-lymphocytic leukemia
ANLL,acute nonlymphocytic leukemia
anti-HCV,antibody to Hepatitis C Virus
anti-Xa,anti-Factor Xa IU
anti-Xa,anti-factor Xa
AOM TT,Acute Otitis Media with Tympanostomy Tubes
AP,alkaline phosphatase
APC,aminopentane carboxylic acid
APCs,atrial premature contractions
APD,action potential duration
apo B,apolipoprotein B
Apo B,apolipoprotein B
ApoB,apolipoprotein B
APR,acute phase reaction
APR,allergic perennial rhinitis
APTC,Anti-Platelet Trialists' Collaborations
aPTT,and Lymphatic System: partial thromboplastin time
aPTT,Activated partial thromboplastin time
APTT,activated partial  thromboplastin time
aPTT,activated  partial thromboplastin time
APTT,Activated partial thromboplastin times
APTTs,activated partial thromboplastin times
APTTs,activated partial thromboplastin  times
AQLQ(S),Asthma Quality of Life Questionnaire
ara-A,9-?-D-arabinofuranosyladenine
ara-A,#NAME?
ARB,angiotensin receptor blocker
ARB,angiotensin II receptor blocker
ARBs,angiotensin receptor blockers
ARCI,Addiction Research Center Inventories
ARDS,adult respiratory distress syndrome
ARDS,Acute Respiratory Distress Syndrome
ARDS,unknown.Adult Respiratory Distress Syndrome
ARDS,amiodarone.Adult Respiratory Distress Syndrome
ART,Assisted Reproductive                 Technologies
ART,Assisted Reproductive Technology
ART,Assisted                   Reproductive Technologies
ART,Assisted Reproductive Technologies
ASA,American Society of Anesthesiologists
ASAS,Assessment in Ankylosing Spondylitis
ASCOT,Anglo-Scandinavian Cardiac Outcomes Trial
ASQ,Ages & Stages Questionnaire
ASQoL,Ankylosing Spondylitis Quality of Life Questionnaire
ASR,application site reaction
ASRs,application site reactions
AST,aspartate aminotransferase
AST,"align=""left"">&#160;&#160;&#160;&#160;Elevated SGOT"
AST,"align=""left"" colspan=""1"" rowspan=""1"">SGOT"
AST,aspartate transaminase
AST,and increased SGOT
AST,and Endocrine                                                           Increased SGOT
AST,aspartate  transaminase
AST,<tr><td/><td>&#8593;Aspartate aminotransferase
AST,and Endocrine: increased SGOT
AST,aspartate amino – transferase
ATNAA,ADMINISTRATION and Patient Instruction Sheet
ATP,adenosine triphosphate
AtroPen®,atropine which could result in temporary incapacitation (inability to walk properly
AtroPen®,and Caregiver Directions for Use at the end of this package insert
atropine,Atropine Injection
AU/mL,Allergy Units/mL
AUA,American Urological Association
AUC,area under the curve
AUC,area under the concentration-time
AUC,area under the concentration-time curve
AUC,[area under the curve
AUC,area under the concentration time curve
AUC,area under the concentration time-curve
AUC,area under the  curve
AUC,area  under the concentration-time
AUC,Area Under Curve
AUC,and                       bioequivalence
AUC,area under the concentration  time-curve
AUC,area under the  concentration time curve
AUC,area under the time/plasma concentration curve
AUC,area under the plasma concentrationtime curve
AUC,area under the concentration-time  curve
AUC,area-under-the-curve
AUC,area-under-the plasma-concentration curve
AUC,and bioequivalence
AUC,area-under-the-plasma-concentration curve
AUC,area  under the curve
AUC,area-under-the-time/concentration curve
AUC,at doses which produced exposures
AUC,area under the plasma concentration curve
AUC,about 2-fold the systemic exposure
AUC,about 2 fold the systemic exposure
AUC values,and reproductive performance were not affected in rats at plasma exposures
AUC?,area under the curve to infinity
AUC?,area under the  curve to infinity
AUCs,affords minimal peak serum levels and systemic exposure
AUCs,areas under plasma concentration-time curves
AUCs,area under the plasma concentration curves
AUCs,areas under plasma concentration- time curves
AUCs,a measure of systemic exposure
AUCs,a dose resulting in total systemic drug exposure
AUCs,a measure of  systemic exposure
AUPC,area under the pain curve
AUR,Acute urinary retention
autoimmune,adults Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Secondary thrombocytopenia in adults Acquired
autoimmune,antituberculous chemotherapy; aspiration pneumonitis.Hematologic disorders: idiopathic thrombocytopenic purpura in adults; secondary thrombocytopenia in adults; acquired
autoimmune,antituberculous chemotherapyAspiration pneumonitisHematologic DisordersHematologic DisordersIdiopathic thrombocytopenic purpura in adultsSecondary thrombocytopenia in adultsAcquired
AV,atrioventricular
A-V,atrioventricular
AWR,airways resistance
AWR,airway resistance
AZA,Azathioprine
AZA,Tacrolimus/Azathioprine
AZA,Prograf/Azathioprine
B.  fragilis,Bacteroides fragilis group
B. fragilis,Bacteroides fragilis group
b.i.d.,be administered orally twice daily
B/H,bisoprolol/hydrochlorothiazide
B17P,betamethasone  17-propionate
B17P,Betamethasone 17-propionate
B19V,B19 virus
B-21-MP,beclomethasone-21-monopropionate
bacterial,been reported following local use of corticosteroids.The development of secondary ocular infection
BALs,Bronchoalveolar lavages
BAO,basal acid output
BARS,Barnes Akathisia Rating Scale
BARS,Behavioural Activity Rating  Scale
BARS,Behavioural Activity Rating Scale
Baseline,baseline and the post-ingestion measurements
BASFI,Bath Ankylosing Spondylitis Functional Index
Basil,Basilicum
BAT,Bivalirudin Angioplasty Trial
BCDFE,2-bromo-2-chloro-1
BCPT,Breast Cancer Prevention Trial
BE,Barrett's Esophagus
BE,Barrett’s Esophagus
betadex,betacyclodextrin
bexarotene,bexarotene.®
BHA,butylated hydroxyanisole
BHAT,Beta-Blocker Heart Attack Trial
BHPM,[bis-(p-hydroxyphenyl) pyridyl-2 methane;
BHT,butylated hydroxytoluene
BIS,Behavior and Ideation Scale
BIS,Behavior  and Ideation Scale
Bitartrate,bitartrate injection
Bitartrate,bitartrate  injection
BLU-U,Blue Light Photodynamic Therapy Illuminator
BMD,bone mineral density
BMD,bone mineral
BMI,body mass index
BMI,body mass indices
BMI,body mass  index
BMT,bone marrow transplant
BMT,bone  marrow transplant
BMT,bone marrow transplantation
BOH,beclomethasone
bone,"<br/>3.0<br/>2.2<br/>2.4<br/>2.4<br/>1.4<br/>1.6<br/>1.6<br/>1.1<br/>1.1</td>                         </tr>                         <tr>                            <td>                               <content styleCode=""italics"">Musculoskeletal  </content>                               <br/>&#160;&#160;&#160;&#160;&#160;musculoskeletal"
bone,by examination of additional tissues and fluids
bone,by examination of additional  tissues and fluids
BOP,bleeding-on-probing
botanicals,botanical medicines
bottle,bottles of 100 and 500.100's
bottle,bottles of 100 and 500 100’s
BP,blood pressure
BPAR,biopsy proven acute rejection
BPD,Bronchopulmonary Dysplasia
BPH,benign prostatic hypertrophy
BPH,BENIGN PROSTATIC HYPERPLASIA
BPH,:Benign prostatic hyperplasia
BPP,biophysical profiling
BPRS,Brief Psychiatric Rating Scale
BPRS-A,Brief Psychiatric Rating Scale
BPRS-A,Brief  Psychiatric Rating Scale
bronopol,2-bromo-2-nitropropane-1
broth,based on a microdilution method
broth,be interpreted according to the following criteria:1
broth,be interpreted according to the following criteria:2
broth,be determined using a standardized procedure based on dilution methods
broth,be interpreted according to the following criteria:4
broth,be interpreted according to the following criteria.2
BSA,body surface area
BSC,Best Supportive Care
BSP,bromsulphalein
BSP,bromsulfophthalein
BSPS,Brief Social Phobia Scale
BSS,baseline signs and symptoms
BSS,bismuth subsalicylate
BT,Bioactive serum testosterone concentrations
BTM,bone turnover markers
BU/CY,busulfan/cyclophosphamide
BUD,budesonide
BUN,blood urea increased
BUN,blood urea nitrogen
BUN,libido<br/>Rhinorrhea<br/>Flushing<br/>Hyperuricemia<br/>Hyperglycemia<br/>Hyponatremia<br/>Hypochloremia<br/>Increase  in serum urea nitrogen
BUN,blood urea  nitrogen
BUN,Creatinine/Blood Urea Nitrogen
BUN,<tr><td/><td>&#8593;Blood urea nitrogen
BUN,blood urea nitrogen level
busulfan,BUSULFEX Clinical Trials In the BUSULFEX
busulfan,BUSULFAN-INDUCED PANCYTOPENIA IN HUMANS.®
Butalbital,butalbital component of ASCOMP® with Codeine
BW,body weight
BWSQ,Benzodiazepine Withdrawal Symptom Questionnaire
BZ,benzodiazepine
C Cr,creatinine clearance
c.i.,"colspan=""5"" align=""left"">"
C15H25NO3,1-(isopropylamino)-3-[(C15H25NO3)2 -C4H6O6
C17H19NO3,formula:(C17H19NO3)2•H2SO4????????????Molecular Weight: 668.77
C1EI,C1 esterase inhibitor
C6G,codeine-6-glucuronide
CA,Carbonic anhydrase
CAARS,Conners Adult ADHD Rating Scale Screening Version
CABG,coronary artery bypass graft
CABG,coronary artery bypass  graft
CABG,coronary artery bypass grafting
CABG,coronary artier bypass graft
CABG,“coronary artery bypass graft
CABP,community-acquired bacterial pneumonia
CAD,Coronary Artery Disease
CAD,1.2
CAF,chronic atrial fibrillation
CA-II,carbonic anhydrase II
calcitriol,calcipotriene is expected to be similar to that of the naturally occurring vitamin.3
Calcium,calcium phosphate
Calcium,calcium carbonate
CALGB,Cancer and Leukemia Group B
cAMP,Cilostazol and several of its metabolites arecyclic AMP
cAMP,cyclic AMP
cAMP,cyclic-3'
c-AMP,cyclic-3'
c-AMP,cyclic-3?
c-AMP,cyclic adenosine monophosphate
camphor,Camphora
CAP,community-acquired pneumonia
CAP,community acquired pneumonia
CAPD,continuous ambulatory peritoneal dialysis
CAPD,chronic ambulatory peritoneal dialysis
CAPD,continuous ambulatory peritoneal  dialysis
CAPOZIDE®,captopril and hydrochlorothiazide tablets
CAPS,Clinician-Administered PTSD Scale Part 2
CAPS-2,Clinician-Administered PTSD Scale Part 2
CARDS,Collaborative Atorvastatin Diabetes Study
CARE,Cholesterol and Recurrent Events
CAST,Cardiac Arrhythmia Suppression Trial
CAVHD,continuous arteriovenous hemofiltration/dialysis
CBC,complete blood count
CBER,Center for Biologics Evaluation and Research
CBF,cerebral blood flow
CBG,corticosteroid binding globulin
CBG,corticosteroid-binding globulin
CBG,corticosteroid  binding globulin
cbl,cofactor metabolism
CBS,cystathionine beta-synthase
CBS,in:cystathionine beta-synthase
CBS,.cbl).cystathionine beta-synthase
CBZ,Carbamazepine
CBZ,ConcentrationPhenytoinNC or 25% increasea48% decreaseCarbamazepine
CBZ,"valign=""top"">Carbamazepine"
CBZ,"valign=""top"">&#160;Carbamazepine"
CBZ-E,Carbamazepine-10
CCa,Albumin-corrected serum calcium
CCa,insufficiency.*Albumin-corrected serum calcium
CCAIT,Canadian Coronary Atherosclerosis Intervention Trial
CCB,calcium channel blocker
CCG,Cancer Group
CCK,cholecystokinin
CCR,conventional care regimens
CCr,creatinine clearance
CCyR,complete cytogenetic response
CCyR,complete cytogenetic response rate
CD15,cluster of differentiation 15
CDAD,Clostridium difficile associated diarrhea
CDC,Center for Disease Control
CDC,Centers for Disease Control and Prevention
CDC,Centers for Disease Control
CDRS-R,Childhood Depression Rating Scale-Revised
CDRS-R,Childhood Depression  Rating Scale-Revised
CDRS-R,Childhood Depression Rating  Scale-Revised
CDRS-R,Children’s Depression Rating Scale - Revised
CE,conjugated  estrogens
CE,conjugated estrogen
CE,conjugated equine estrogens
CE,conjugated estrogens
CE,clinically evaluable
CE/MPA,conjugated estrogens plus 2.5 mg medroxyprogesterone acetate
CE/MPA,conjugated  estrogens plus 2.5 mg medroxyprogesterone acetate
CE/MPA,conjugated equine estrogens plus 2.5 mg medroxyprogesterone acetate
CEA,carcino-embyrogenic antigen
CEA,carcino-embryogenic antigen
Cefizox,ceftizoxime for injection
Cefizox,ceftizoxime injection
Cefizox®,ceftizoxime for injection
Cefizox®,ceftizoxime injection
CEFOTAN,cefotetan disodium for injection
CEFOTAN,cefotetan injection
celite ACT,celite Activated Clotting Time
CFC,chlorofluorocarbon
CFCs,chlorofluorocarbons
CFCs,chlorfluorocarbons
CFC's,chlorofluorocarbons
CFTR,cystic fibrosis transmembrane conductance regulator
CFU,colony  forming units
CFU,colony forming units
CFUs,colony forming units
CG,cisplatin and gemcitabine
CgA,Chromogranin A
CGI,Clinical Global Impression
CGI,Clinical Global Impressions
CGI,Clinical Global  Impressions
CGI,Clinical Global  Impression
CGI-BP,Clinical Global Impression - Bipolar
CGIC,clinician's global impression of change
CGI-C,Clinical Global Impression - Change
CGI-I,Clinical Global Impression-Global Improvement Scale
CGI-I,Clinical Global Impression of Improvement
CGI-I,Clinical Global Impression-Global Improvement
CGI-I,Clinical Global Impression-Improvement
CGI-I,Clinical  Global Impression of Improvement
CGI-S,Clinical Global Impression Severity of Illness
CGI-S,Clinical Global Impression – Severity of Illness
CGI-S,Clinical Global  Impression-Severity of Illness Scale
cGMP,cyclic  guanosine monophosphate
cGMP,cyclic guanosine monophosphate
cGMP,cyclic guanosine                                         monophosphate
cGMP,cyclic guanosine                                     monophosphate
cGMP,current good manufacturing practices
cGMP,current good manufacturing practice
cGMP-PDE,cyclic-3'
CHAQ-DI,Childhood Health Assessment Questionnaire Disability Index
CHC,Chronic Hepatitis C
CHC,
CHD,coronary heart disease
chewable,conversion to monotherapy with lamotrigine tablets
chewable,chronic treatment with lamotrigine tablets
CHF,congestive heart failure
CHF,.Congestive Heart Failure
CHF,
Children,clarithromycin immediate-release tablets and clarithromycin for oral suspension
CHL,Chinese hamster lung
Chlamydia,Chlamydophila
CHO,Chinese Hamster Ovary
CHO,Chinese                                     Hamster Ovary
CHO,Chinese  Hamster Ovary
CHO,Chinese Hamster  Ovary
CHR,complete hematologic response
CI,confidence intervals
CI,confidence interval
CI,cardiac index
cIAI,complicated intra-abdominal infections
CIBIC,Clinician’s Interview Based Impression of Change
CIBIC,Clinician's Interview-Based Impression of Change
cimetidine,clearance of diazepam and certain other benzodiazepines can be delayed in association with Tagamet
cimetidine,clearance of diazepam and certain other benzodiazepines can be delayed in association with Tagamet®
cimetidine,clearance of diazepam and certain other benzodiazepines can be delayed in  association with Tagamet®
cIMT,carotid intimal-medial thickness
CINV,chemotherapy induced nausea and vomiting
CIU,chronic idiopathic urticaria
CJD,Creutzfeldt-Jakob disease
CK,creatine kinase
CKD,chronic kidney disease
CL,clearance
Cl-,chloride
Cl–,chloride
Cl?,Chloride
Cl¯,Chloride
CLBP,chronic low back pain
CLCR,clearance and creatinine clearance
Clcr,Calculate Creatine Clearance
CLD,chronic liver disease
clear,CARBOCAINE is a local anesthetic available as sterile isotonic solutions
CLL,chronic lymphocytic leukemia
CLL,14.4
CLL,dose.Chronic Lymphocytic Leukemia
CLORPRES®,clonidine hydrochloride USP/chlorthalidone USP
CLr,clearance
CLSI,Clinical Laboratory and Standards Institute
CLSI,Clinical and Laboratory Standards Institute
CLSI,control  strainsClinical and Laboratory Standards Institute
Cmax,changes in rate or extent of lomefloxacin exposure
Cmax,concentration of glimepiride or pioglitazone or peak exposure
CML,Chronic Myelogenous Leukemia
CML,chronic myeloid leukemia
cMLSB,constitutive macrolide-lincosamide-streptogramin B
CMMoL,chronic myelomonocytic leukemia
CMV,cytomegalovirus
CNI,calcineurin inhibitors
CNS,central nervous system
CNS,drowsiness/confusion/depression/anxiety/nervousness
CNS,central nervous systems
CNS,CENTRAL N E RVOUS SYSTEM
CNS,central  nervous system
CNS,central nervous             system
CNV,choroidal neovascularization
COC,contraceptive
COCs,contraceptives
Codeine,codeine phosphate
Codeprex,codeine polistirex and chlorpheniramine polistirex
Comb,Combined Metformin/Glyburide
Comb,Combined Metformin Hydrochloride Tablets/Glyburide
Comb,Combined Metformin Hydrochloride/Glyburide
COMT,catechol-O-methyltransferase
cont.,"<tr><td><content styleCode=""underline"">Cardiovascular"
COPD,chronic obstructive pulmonary disease
cortisone,Cortisone aceticum
COSTART,Coding Symbols for Thesaurus of Adverse Reaction Terms
COSTART,classified into standard dictionary
Cough:,Cough.
COX-1,cyclooxygenase-1
COX-2,cyclooxygenase-2
COX-2,cyclooxgenase-2
CPAP,continuous positive airway pressure
CPB,cardiopulmonary bypass
CPK,creatine phosphokinase levels
CPK,creatine phosphokinase
CPK,creatinine phosphokinase
CPR,cardiopulmonary resuscitation
CPS,complex partial seizures
CPS,complex  partial seizures
CPS,complex partial seizure
CR,Carbidopa-Levodopa
CR,[complete responses
CR,Complete response
CR,<br/>Complete <br/>Response
CR,<br/>Complete Response
CR+PR,cytogenetic response rate
CR+PR,"<content styleCode=""bold"">Overall Response Rate"
CR+PR,"<content styleCode=""bold"">Duration of Response</content>                                     <br/>Median time to"
CRC,Child Resistant Control
CrCl,creatinine clearance
CRI,Chronic Renal Insufficiency
CRP,C-reactive protein
CSBM,Complete Spontaneous Bowel Movement
CSF,cerebrospinal fluid
CSF,cerebral spinal fluid
CSFP,cerebrospinal fluid pressure
CSOM,Chronic Suppurative Otitis Media
Css,concentration  of morphine at steady state
Css,concentration  of morphine at steady-state
Css,concentration of morphine at steady state
cSSSI,complicated skin and skin structure infections
cSSSI,Complicated Skin and Skin Structure Infection
CST,Contraction stress testing
CT,citalopram
CT,computerized tomographic
CT,computerized tomography
CT,citalopram 
CT,computed tomography
CT,
CTC,Common Toxicity Criteria
CTCAE,Common Terminology Criteria for Adverse Events
CTCL,cutaneous T-cell lymphoma
CTCL,cutaneous T-cell                                     lymphoma
CTP,Child-Turcotte-Pugh
Ctrough,cyclosporine trough concentrations
CTZ,chemoreceptor  trigger zone
CTZ,chemoreceptor trigger zone
CUE,cumulative urinary excretion
CUE,cumulative urinary  excretion
cure,clinical success rate
cure,clinical success  rate
cUTI,complicated urinary tract infections
CV,cardiovascular
CV,coefficient of variation
CV,coefficient of variances
CV%,coefficient of variation
CV%,coefficients of variation
CVA,cerebrovascular accident
CVC,central venous catheter
CVD,cardiovascular disease
CVP,central venous pressure
CY/TBI,cyclophosphamide/total body irradiation
CYBOCS,Children’s Yale-Brown Obsessive-Compulsive Scale
CY-BOCS,Children's Yale-Brown Obsessive Compulsive Scale
CY-BOCS,Children’s Yale-Brown Obsessive Compulsive Scale
cyclic AMP,cyclic-3'
cyclic AMP,cyclic-3’
cyclic GMP,cyclic guanosine monophosphate
cyclical,"<content styleCode=""bold"">Conjugated Estrogens 0.625 mg + PROMETRIUM Capsules 200 mg"
CYP,cytochrome P450
CYP,cytochrome P450 isoenzymes
CYP  3A4,cytochrome P-450 3A4
CYP 2C9,cytochrome P450 2C9 enzyme
CYP 2D6,cytochrome P450 2D6
CYP 3A,cytochrome P450 3A
CYP 3A4,cytochrome P-450 3A4
CYP 3A4,cytochrome P450 3A4
CYP1A2,cytochrome P450 1A2
CYP2C19,cytochrome P450 2C19
CYP2C19,cytochrome P450 2C19
CYP2D6,cytochrome P450 2D6
CYP2D6,cytochrome P450 isoform 2D6
CYP2D6,cytochrome P450  isoform 2D6
CYP2D6,cytochrome  P450 2D6
CYP2D6,cytochrome P450 2D6
CYP3A,cytochrome P450 3A
CYP3A,cytochromes P450 3A
CYP3A,cytochrome  P450 3A
CYP3A,cytochrome P-450 3A
CYP3A,cytochromes P450 3A
CYP3A,cytochrome P4503A
CYP3A,cytochrome P450 3A
CYP3A,cytochrome P450 33A
CYP3A4,cytochrome P450 3A4
CYP3A4,cytochrome P450 isozyme 3A4
CYP3A4,cytochrome P450 isoform 3A4
CYP3A4,cytochrome P-450 3A4
CYP3A4,cytochrome P450 3A4 isoenzyme system
CYP3A4,cytochrome P450 3A4 enzyme
CYP3A4,cytochromes P450 3A4
CYP3A4,Cytrochrome P450 3A4
CYP3A4,cytochrome P450  3A4 isoenzyme system
CYP3A4/5,cytochrome P450 3A4/5
CYP450,cytochrome P450
D.A.S.,Differential Ability Scale
D/C,discontinuations
D2,dopamine type 2
D5/W,diluted with 5% dextrose in water
DA,dopamine
DAI,Disease Activity Index
Dantrium,dantrolene sodium
dapsone,diaminodiphenylsulfone and its structural formula is:12HEach gram of ACZONE™
DAT,direct antiglobulin test
DB106,disperse blue 106
DBP,diastolic blood  pressure
DBP,diastolic blood pressure
DCCT,Diabetes Control and Complications Trial
DCIS,Ductal Carcinoma in Situ
DCIS,tamoxifen.Ductal Carcinoma in Situ
DCIS,years.Ductal Carcinoma in Situ
DCIS,therapy.Ductal Carcinoma in Situ
DCT,demethylcitalopram
DDC,dopa decarboxylase
ddC,2'
DDCT,didemethylcitalopram
ddI,didanosine
ddI,"rowspan=""1"">didanosine"
ddU,dideoxyuridine
DEA,N-desethylamiodarone
DEA,.N-desethylamiodarone
DEA,Drug Enforcement Administration
DEA,Drug Enforcement  Administration
DEA,desethylamiodarone
death,dose was associated with maternal toxicity
DEHP,di-2-ethylhexyl phthalate
DEHP,di 2-ethylhexyl phthalate
DEHP,di-(2- ethylhexyl)phthalate
DEHP,di-(2-ethylhexyl)phthalate
DEHP,di-2-ethylhexylphthalate
DEHP,di-2-ethylhexyl phthlate
DEHP,di-2-ethylhexyl                             phthalate
delta-9-THC,delta-9-tetrahydrocannabinol
DEO,N-desethyloxybutynin
DES,diethylstilbestrol
DEXA,dual energy x-ray absorptiometry
DEXA,dual energy x?ray
DF,disoproxil fumarate
DFS,disease-free survival
DFS,"styleCode=""bold"">Disease Free  Survival"
DHA,Docosahexaenoic Acid
DHA,dapsone hydroxylamine
DHD,10
DHEA-S,dehydroepiandrosterone sulfate
DHFR,dihydrofolate reductase
DHT,dihydrotestosterone
DHT,5?-dihydrotestosterone
Diarrhea,diarrhea
diazepam,diazepamVALIUM®
DIC,disseminated intravascular coagulation
DIG,Digitalis Investigation Group
diluted,PRECAUTIONS.Drug InteractionsDrug InteractionsAdditives may be incompatible with the reconstituted
DIOS,distal intestinal obstruction syndrome
Diovan,Diovan HCT is the combination tablet of valsartan
DIP,distal interphalangeal
Disorder,Disorder: 116 subjects
DIT,diiodotyrosine
DLT,dose limiting toxicity
DLV,delavirdine
DMA,Dimethylacetamide
DMA,N
dMAC,disseminated MAC
DMARDs,disease-modifying anti-rheumatic drugs
DMARDs,disease modifying anti-rheumatic drugs
DMBA,dimethylbenzanthracene
DMSO,dimethyl sulfoxide
DMSO,dimethylsulfoxide
DNA,deoxyribonucleic acid
DNA,deoxyribonu cleic acid
DNR,daunorubicin
DOI,Definition of Improvement
DOPA,dihydroxyphenylalanine
DOPC,1
Dose A,dose of approximately 0.033
DOT,Directly Observed Therapy
DOT,.Directly Observed Therapy
DOXIL,doxorubicin HCl liposome injection
DOXIL,doxorubicin HCl  liposome injection
DPN,diabetic peripheral neuropathy
DPNP,Diabetic Peripheral Neuropathic Pain
DPP-4,dipeptidyl peptidase-4
DPPG,1
DR,duration of response
DRC,Data Review Committee
DRESS,drug rash with eosinophilia and systemic symptoms
DRSP,Daily Record of Severity of Problems
Drugs,Drug Interactions.
drying,Diphenhydramine hydrochloride is an antihistamine with anticholinergic
drying,Drug Interaction MAO inhibitors prolong and intensify the anticholinergic
DSA,Digital Subtraction Angiography
DSI,DNA synthesis inhibition
DSM,Diagnostic and Statistical Manual
DSMB,Data Safety Monitoring Board
DSMBs,Data and Safety Monitoring Boards
DSM-III,Diagnostic and Statistical Manual of Mental Disorders-3rd edition
DSM-III,Diagnostic and Statistical Manual of Mental Disorders - 3rd edition
DSM-III,Diagnostic and Statistical  Manual of Mental Disorders-3rd edition
DSM-III,Diagnostic and Statistical Manual of Mental Disorders3rd edition
DSM-IV,DSM-IV.Social Anxiety Disorder
DSS,Disability Scale Score
DSST,digit-symbol substitution test
DSST,Digit Symbol Substitution Test
DST,dexamethasone suppression test
DST,patients.Dexamethasone suppression test
DST,use.Dexamethasone suppression test
DTPA,99mTc-diethylenetriaminepentaacetic acid
DU,diazolidinyl urea
DV,Daily Value
DVT,deep vein thrombosis
DVT,deep vein  thrombosis
DX/DM,dextrorphan/dextromethorphan
DXA,dual-energy x-ray absorptiometric
dyspepsia,dyspeptic signs and symptoms
dysphagia,defined as complete resolution in clinical symptoms of esophageal candidiasis
E coli,Escherichia coli
E.,Escherichia
E.,.Escherichia
E. coli,Escherichia coli
E.F.A.D.,essential fatty acid deficiency
e.g,effects of digitalis
e.g.,exogenous amines
e.g.,enzyme-inducing AED
e.g.,experience changes in mood
e.g.,enzyme-inducing agents
e.g.,ergot alkaloids
e.g.,ergotamine and macrolide antibiotics
e.g.,effector organ
e.g.,each other.1 agonists
e.g.,existing treatment regimen
e.g.,environmental agents
E.G.,EQUIPMENT CONTAINING ALUMINUM
e.g.,exaggerated response
e.g.,e.g.:macrolide antibiotics
e.g.,ergot alkaloid drugs
e.g.,estrogens
e.g.,effects of digitalis
e.g.,esophagitis or GERD symptoms
e.g.,emptying
e.g.,Electrocardiogram changes
e.g.,exaggerated pharmacological effects
e.g.,exaggerated sunburn reactions
e.g.,estradiol-containing drug products
e.g.,enhancing                                             insulin secretion
e.g.,effects of other drugs
e.g.,elevated triglycerides
e.g.,endogenous metals
e.g.,evaluate the specific pathology
E.O.E.,end of elution
E®,emollient cream
EAE,encephalomyelitis
EBCTCG,Early Breast Cancer Trialists Collaborative Group
EBCTCG,Early Breast Cancer Trialists' Collaborative Group
EBCTCG,Early Breast Cancer Trialists’ Collaborative Group
EBMT,European Group for Blood and Marrow Transplantation
EBV,Epstein Barr Virus
ECG,Electrocardiogram
ECG,electrocardiographic
ECGs,Electrocardiograms
ECG's,electrocardiograms
ECL,electrochemical luminescence
ECL,electrochemiluminescent
ECL,electrochemiluminescence
ECL,Enterochromaffin                            -like
ECL,Enterochromaffin-like
eCLcr,estimated creatinine clearance rates
ECOG,Eastern Cooperative Oncology Group
ECOG,Eastern Cooperative                                 Oncology Group
ECT,electroconvulsive therapy
ECT,treatment.Electroconvulsive therapy
ECT,stopped.Electroconvulsive therapy
ECT,hydrobromide.Electroconvulsive Therapy
ECT,citalopram.Electroconvulsive Therapy
ED,erectile dysfunction
EDDP,2-ethylidene-1
EDDP,2-ethylidene1
EDE,effective dose equivalent
EDE,Effective dose equivalents
Edema,edema
EDRF,endothelium-derived relaxing factor
EDSS,expanded disability status scale
EDTA,ethylenediamine tetraacetic acid
EDTA,ethylene diamine tetraacetic acid
EDTA,ethylenediaminetetraacetic acid
EDTMP,ethylenediaminetetramethylenephosphonic acid
EE,Erosive Esophagitis
EE,ethinyl estradiol
EE,ethinylestradiol
EEAD,evoked after-discharge
EEF,enhancement factor
EEG,electroencephalogram
EF,ejection  fraction
EFA,essential fatty acid
EFAD,essential fatty acid deficiency
EFAD,essential fatty                             acid deficiency
EFAD,essential                             fatty acid deficiency
eg,emergency                                                   setting
eg,emergency setting
eg,exaggerated response
eg,esophagitis or GERD symptoms
eg,Electrocardiogram changes
eg,effects of digitalis
EGSA,Evaluator's Global Severity Assessment
EIB,exercise-induced bronchoconstriction
EIB,exercise-induced bronchospasm
ELF,epithelial lining fluid
ELISA,enzyme?linked immunosorbent assay
ELISA,enzyme-linked immunosorbent assay
ELISAs,Enzyme?linked immunosorbent assays
EM,extensive metabolizers
EMC,encephalomyocarditis virus
EMD,arrest/electromechanical dissociation
EMs,[extensive metabolizers
EMs,extensive  metabolizers
EMs,extensive metabolizers
ENF,enfuvirtide
ENL,14.2.
ENL,Erythema nodosum leprosum
ENLON,edrophonium chloride injection
ENTIS,European                 network of teratology information services
EOS,end of synthesis
EOT,End of Titration
EOT,end of treatment
EOT,end of therapy
EOW,every other week
EPA,Eicosapentaenoic Acid
EPA,Environmental Protection Agency
EPA’s,Environmental Protection Agency’s
EPA's,Environmental Protection Agency's
EPS,extrapyramidal symptoms
EPS,Extrapyramidal Reactions
EPS,extrapyramidal syndrome
EPS,Extrapyramidal Syndromes
EPS,extrapyramidal  symptoms
EPS,.Extrapyramidal Reactions
EPS,EffectsExtrapyramidal Symptoms
EPS,expressed prostatic secretion
EPS,extrapyramidal signs and symptoms
EPT,electric pulp testers
ER,estrogen receptor
ER,Extended-release
ERA,Endothelin Receptor Antagonist
ERAFT,[(European Rythmonorm SR Atrial Fibrillation Trial
ERCP,endoscopic retrograde cholangiopancreatography
ERG,electroretinogram
ERICA,Efficacy of Ranolazine In Chronic Angina
ERP,effective refractory period
ES,Erosion Score
ESAs,erythropoiesis stimulating agents
ESAs,erythropoiesis-stimulating agents
ESI,“events of special interest”
ESR,erythrocyte sedimentation rate
ESRD,end-stage renal disease
ESRD,end stage renal disease
ESRD,end-stage renal                                             disease
Estraderm®,estradiol transdermal system
Estradiol,17?-estradiol
ESVEM,[Electrophysiologic Study Versus Electrocardiographic Monitoring
ETEC,enterotoxigenic  strains of Escherichia coli
ETEC,enterotoxigenic strains of Escherichia coli
Ethiodol,ethiodized oil for injection
ETT,exercise tolerance time
ETT,Exercise Tolerance Test
EVA,ethylene vinyl acetate
Events,events
EXCEL,Expanded Clinical Evaluation of Lovastatin
EXCEL,Expanded Clinical Evaluation Of Lovastatin
EXCEL,agents.EXPANDED CLINICAL EVALUATION OF LOVASTATIN
EXP,expiration
F/U,follow-up period
FA,following termination of anesthesia
FAB,French-American-British
FACT-L,Functional Assessment of                                             Cancer Therapy-Lung
FACT-L,Functional Assessment of Cancer Therapy-Lung
FAMVIR,FAMVIR-treated patients with herpes zoster
FAMVIR,FAMVIR-treated patients with recurrent genital herpes
FAMVIR,FAMVIR-treated patients with herpes labialis
FATS,Familial Atherosclerosis Treatment Study
FBG,fasting blood glucose
FCT,fever clearance time
FEF25-75%,forced expiratory flow over 25-75% of the vital capacity
FEF25-75%,forced expiratory flow  over 25-75% of the vital capacity
female,SystemNausea31%12%Constipation8%5%Anorexia8%4%Vomiting4%2%Flatulence4%3%Metabolic/NutritionalWeight Loss3%0%Nervous SystemDizziness20%9%Somnolence17%8%Insomnia17%11%Dry Mouth12%6%Nervousness10%5%Abnormal Dreams47%2%Tremor5%2%Depression3%<1%Paresthesia3%1%Libido Decreased3%<1%Agitation3%1%Respiratory SystemPharyngitis7%6%Yawn3%0%SkinSweating14%3%Special SensesAbnormal Vision54%<1%Urogenital SystemAbnormal Ejaculation16%<1%(male)6
FEV 1,forced expiratory volume 1 second
FEV1,forced expiratory volume 1 second
FEV1,forced expiratory volume in 1 second
FEV1,[forced expiratory volume in 1 second
FGF,fibroblast growth factor
FH,familial hypercholesterolemia
FIQ,Fibromyalgia Impact Questionnaire
FISH,fluorescence in situ hybridization
FIT,Fracture Intervention Trial
FIT,Fracture Intervention  Trial
flare,full glass of liquid.Patients should be informed that transient exacerbation
Flat,FL 33637                         ©Bausch & Lomb Incorporated                         9105000
FLIE,Functional Living Index–Emesis
FLS,flu-like symptoms
Fluid,"Fluid</content>                            </td>                            <td>                               <content styleCode=""bold"">Ratio of Fluconazole Tissue"
FLUOR-OP,fluorometholone ophthalmic suspension
FM,fibromyalgia
FMF,familial Mediterranean fever
FMH,fatal massive hemoptysis
FML-S®,fluorometholone and sulfacetamide sodium  ophthalmic suspension
FN,false negative
folic acid,Folic Acid
for EPS,from  those trials on the Simpson-Angus Rating Scale
for EPS,from those trials on the Simpson-Angus Rating Scale
formic acid,Formicum acidum
FP,false positive
FPG,fasting plasma glucose
FPG,fasting  plasma glucose
FQ-SPS,Fear Questionnaire Social Phobia Subscale
free,3-fold higher than the non-protein-bound
FSH,follicle stimulating hormone
FSH,follicle-stimulating hormone
FT4I,free-T4 index
FT4I,free T4 index
FTM,Fumarate and Polysaccharide Iron Complex
FUPA,5-fluoro-ureido-propionic acid
FVC,forced  vital capacity
FVC,forced vital capacity
G.I.,gastrointestinal
g/dL,"<tr><td>&#160;&#160;&#160;&#160;&gt;5.5 mg/L</td><td>30</td><td>31</td></tr> <tr><td><content styleCode=""bold"">Serum M-protein"
G6PD,vulgaris.Glucose 6-phosphate dehydrogenase
G6PD,glucose-6-phosphate dehydrogenase
G6PD,glucose 6-phosphate dehydrogenase
G-6-PD,glucose-6 phosphate dehydrogenase
GABA,gamma-aminobutyric acid
GABA,gamma aminobutyric acid
GABA,gamma-amino-butyric acid
GABA-BZ,gamma-aminobutyric acid-benzodiazepine
GAD,Generalized Anxiety Disorder
GAD,Generalized  Anxiety Disorder
GAD,Generalized Anxiety  Disorder
GAG,glycosaminoglycan
GAS,Global Assessment Scale
GC/MS,gas chromatography/mass  spectrometry
GC/MS,gas chromatography/mass spectrometry
GC/MS,gas  chromatography/mass spectrometry
GC-MF,gas chromatography-mass fragmentography
G-CSF,granulocyte-colony stimulating factor
GCV,ganciclovir
GdDTPA,gadolinium diethylenetriaminepentaacetic acid
GDS,Global Deterioration Scale
Gel,mcg/g once daily for 16 weeks
general,General Disorders and Administrative Site Conditions: Infrequent – edema
GEPR,genetically epilepsy-prone rats
GER,gastroesophageal reflux
GERD,Gastroesophageal  Reflux Disease
GERD,Gastroesophageal Reflux Disease
GERD,patients.Gastroesophageal Reflux Disease
GERD,therapy.Gastroesophageal Reflux Disease
GERD,.GASTROESOPHAGEAL REFLUX DISEASE
GERD,age:GASTROESOPHAGEAL REFLUX DISEASE
GERD,Gastroesophageal Reflux                                 Disease
GFR,glomerular filtration rate
GFR,[glomerular filtration rate
GFR,glomerular filtration rates
GFR,[glomerular  filtration rate
gGT,gamma-glutamyl transpeptidase
GGT,gamma glutamyl transpeptidase
GGT,gamma glutamyltransferase
GGT,gamma-glutamyl transferase
GGT,gamma-glutamyltransferase
GGT,gamma glutamyl                                                   transpeptidase
GH,growth hormone
GH,growth  hormone
GHD,growth hormone deficiency
GI,gastrointestinal
GI,are:Gastrointestinal
GI,patients.Gastrointestinal
GI,4)Gastrointestinal
GI tract,Gastro Intestinal tract
GIR,Glucose Infusion Rate
GIR,Glucose infusion rates
GIST,gastrointestinal stromal tumors
GITS,Gastrointestinal Therapeutic System
GLC,gas-liquid chromatography
GLD,greatest linear dimension
GLP,Good Laboratory Practice
GLP,Good Laboratory Practices
Glyb,Glyburide
GNG,guanines separated by an intervening nucleotide
GnRH,gonadotropin release hormone
GnRH,gonadotropin releasing hormone
GOT,glutamic oxaloacetic transaminase
GPIIb/IIIa,glycoprotein IIb/IIIa
GREPCO,Group for Epidemiology and Prevention of Cholelithiasis
Groups C,group streptococciStreptococcus agalactiae  Streptococci
Groups C,gonorrhoeae Peptostreptococcus species Streptococci
Groups C,Gram-positive MicroorganismsStreptococcus agalactiaeStreptococcus agalactiaeStreptococci
GST,glutathione S-transferase
GST,gold sodium thiosulphate
GTC,generalized tonic-clonic
GTF,glucose tolerance factor
GU,gastric ulcer
GVHD,graft-versus host disease
GX,glycinexylidide
GX,and glycinexylidide
GX,glycine xylidide
H. pylori,Helicobacter pylori
H+,hydrogen inon
H-17-B,Hydrocortisone-17-butyrate
H-17-B,Hydrocortizone-17-butyrate
H2RAs,histamine-2-receptor antagonists
HAART,highly active antiretroviral therapy regimen
HAHA,human anti?human antibody
HAI,histology activity index
HAI,Histologic Activity Index
HAMA,Human anti-mouse antibody
HAMA,human anti-mouse antibodies
HAM-A,Hamilton Rating Scale for Anxiety
HAM-A,Hamilton Anxiety Scale
HAMD,Hamilton Depression Rating  Scale
HAMD,Hamilton Depression Rating Scale
HAM-D,Hamilton Depression Rating Scale
HAPE,high altitude pulmonary edema
HAQ,Health Assessment Questionnaire
HAQ DI,HAQ Disability Index
HAQ-DI,Health Assessment Questionnaire Disability Index
HAQ-DI,HAQ Disability Index
HAV,hepatitis A virus
HAV,HIV and markers for viral hepatitis
HbA1c,hemoglobin A1c
HbA1c,hemoglobin  A1c
HBeAg,HBeAg-positive subjects
HBsAg,Hepatitis B surface antigen
HBsAg,Hepatitis-B Surface Antigen
HBV,hepatitis B virus
hCG,human chorionic gonadotropin
hCG,human chorionic  gonadotropin
HCl,hydrochloride Tablets Product Information for details
HCl,hydrochloride
HCM,hypercalcemia of malignancy
HCT,hydrochlorothiazide
HCTZ,hydrochlorothiazide
HCTZ,combination.Hydrochlorothiazide
HCTZ,bleeding.Hydrochlorothiazide
HCTZ/TA,hydrochlorothiazide/triamterene
HCV,hepatitis C virus
HCV-RNS,HCV replicon cells
HD,hemodialysis
HD,human dose
HDD-CKD,Hemodialysis Dependent-Chronic Kidney Disease
HDL,high-density lipoprotein
HDL,High Density Lipoprotein
HDL,High Density  Lipoprotein
HDL-C,high-density lipoprotein cholesterol
HDL-C,HDL-cholesterol
HDL-C,high density lipoprotein cholesterol
HDLs,High density lipoproteins
HDN,Hemolytic Disease of the Newborn
HDPE,high density polyethylene
HDPE,high-density polyethylene
HDRS,Hamilton Depression Rating Scale
HDRS,Hamilton  Depression Rating Scale
HDRS,Hamilton Depression  Rating Scale
HEC,highly emetogenic cancer chemotherapy
HED,human equivalent dose
heFH,heterozygous familial hypercholesterolemia
HeFH, heterozygous  familial hypercholesterolemia
HEPES,N-2-hydroxyethylpiperazine-N'-2-ethane sulfonic acid
HES/CEL,Hypereosinophilic Syndrome/Chronic Eosinophilic Leukemia
HETEs,hydroxyeicosatetraenoic acids
HF,Heart Failure
HFA BDP,HFA beclomethasone dipropionate
HFIP,hexafluoroisopropanol
HFS,hand-foot syndrome
hFSH,human               follicle-stimulating hormone
hFSH,human follicle-stimulating hormone
HGD,High-Grade Dysplasia
HGD,diffuser.High-Grade Dysplasia
HGPRT,hypoxanthine-guanine phosphoribosyltransferase
HGPRT,hypoxanthine-guanine phosphoribosyltransferase locus
HGPRTase,hypoxanthineguanine phosphoribosyltransferase
HGPRTase,hypoxanthine-guanine phosphoribosyltransferase
HGPRTase,hypoxanthine guanine phosphoribosyltransferase
HI,hepatic insufficiency
HI,hyperinsulinism
high,higher rates of total bilirubin
high dose,have been reported.alcohol*warfarin sodium underdosagephenytoin*aminoglutethimidecyclophosphamide*Pravastatin*amobarbitaldicloxacillinPrednisone*atorvastatin*ethchlorvynolprimidoneazathioprineglutethimidePropylthiouracil*butabarbitalgriseofulvinraloxifenebutalbitalhaloperidolranitidine*carbamazepinemeprobamaterifampinchloral hydrate*6-mercaptopurinesecobarbitalchlordiazepoxidemethimazole*spironolactonechlorthalidonemoricizine hydrochloride*sucralfatecholestyramine*nafcillintrazodoneclozapineparaldehydevitamin C
high dose,have been reported.Specific Drugs ReportedalcoholcyclophosphamidephenytoinaminoglutethimidedicloxacillinpravastatinamobarbitalethchlorvynolprednisoneatorvastatinglutethimideprimidoneazathioprinegriseofulvinpropylthiouracilbutabarbitalhaloperidolraloxifenebutalbitalJantovenTablets  underdosageranitidinecarbamazepinemeprobamaterifampinchloral hydrate6-mercaptopurinesecobarbitalchlordiazepoxidemethimazolespironolactonechlorthalidonemoricizine hydrochloridesucralfatecholestyraminenafcillintrazodoneclozapineparaldehydevitamin C
HIPS,high impact polystyrene
HIT,Heparin-induced Thrombocytopenia
HITT,Heparin-induced Thrombocytopenia and Thrombosis
HITT,Heparin-induced Thromocytopenia and Thrombosis
HIV,human immunodeficiency virus
HIV-1,HIV type 1
HIV-1,Human Immunodeficiency Virus Type 1
HLMs,human liver microsomes
HMG?CoA,3?hydroxy-3?methylglutaryl-coenzyme A
HMG-CoA,3-hydroxy-3-methylglutaryl-coenzyme A
HMG-CoA,3-hydroxy-3-methylglutarylcoenzyme A
HMG-CoA,3-hydroxy-3-methylglutaryl-coenzyme  A
HM-PAO,hexamethylpropylene amine oxime
HMW,High Molecular Weight
HoFH,Homozygous Familial Hypercholesterolemia
HoFH,14.2
HoFH,homozygous familial  hypercholesterolemia
HO-NEF,hydroxynefazodone
HPA,hypothalamic-pituitary-adrenal
HPA,hypothalamic-pituitary- adrenal
HPA,HYPOTHALAMIC-PITUTARY-ADRENAL
HPA,ratio.Hypothalamic-pituitary-adrenal
HPA,hypothalamic pituitary-adrenal
HPA,Hypothalamic- pituitary-adrenal
HPA,Hypothalamic-pituitaIy-adrenal
HPA,hypothalmic-pituitary-adrenal
HPF,high power fields
HPLC,high pressure liquid chromato-graphy
HPLC,high pressure liquid chromatographic
HPLC,high pressure liquid chromatography
HPLC,high pressure liquid  chromatography
HPPH,5-(p-hydroxyphenyl)-5-phenylhydantoin
HPS,Heart Protection Study
HR,hazard ratios
HR,heart rate
HR,[Hazard Ratio
hr,"href=""#footnote-2"">&#8224;</linkHtml>"
hr,pg&#183;hr/ml</td>                               </tr>                               <tr>                                  <td>t<sub>&#189;</sub>
HR,&#160;Hazard ratio
HRT,Hormone Replacement Therapy
HRT,estrogen/hormone replacement therapy
HRT,Estrogen/h                         ormone replacement therapy
HSA,human serum albumin
HSPC,hydrogenated soy phosphatidylcholine
HSR,hypersensitivity reaction
HSRs,hypersensitivity reactions
HSV,herpes simplex virus
HSV-1,HSV types 1
HSV-1,herpes simplex virus types 1
HTM,Haemophilus Test Media
HTM,Haemophilus Test Medium
HTM,Haemophilus  Test Medium
HTM,Haemophilus Testing Medium
HTMS,"styleCode=""italics"">&#946;</content>-hydroxy-7-<content styleCode=""italics"">&#945;</content>-(thiomethyl) spirolactone"
HUMAN,human plasma used in the manufacture of ALBUMIN
HUMAN,Hemodilution may follow administration of ALBUMIN
human,heparin is enhanced by concurrent treatment with antithrombin III
human,heparin is recommended during treatment with antithrombin III
HUS,Hemolytic Uremic Syndrome
HVL,half-value layer
HVOD,Hepatic veno-occlusive disease
HVOD,disease:Hepatic veno-occlusive disease
HYCODAN,hydrocodone bitartrate and homatropine methylbromide
HYCODAN,hydrocodone bitartrate and homatropine                                     methylbromide
hydrous,hydrochloride USP
Hydroxide,hydroxide
i. e.,indicates a catheter complication
i.e.,into a limited
i.e.,in serum glucose
i.e.,in the urea cycle
i.e.,is being  recommended
i.e.,incidences of methotrexate attributed
i.e.,is being recommended
i.e.,"styleCode=""bold"">infusion rate"
i.e.,into the maintenance phase
i.e.,inappropriately
i.e.,increased relative to placebo
i.e.,in electrolytes
i.e.,interval
i.e.,improvement from baseline
i.e.,in pharmacokinetics
i.e.,infusion requirements
i.e.,improvement
i.e.,its active metabolites
i.e.,identified
i.e.,insufficiency
i.e.,initial clearance rates
i.e.,its active  metabolites
i.e.,dose-independent
i.e.,inhibited by muscarine
i.e.,intent-to-treat                                     population
i.e.,warfarin-induced anticoagulant activity
i.e.,impairment
i.e.,in FEV1 after exercise
i.e.,infection
i.e.,independence was first declared
i.e.,interphalangeal joints
i.e.,in the United States
i.e.,initial route of therapy
i.e.,In the controlled adjunctive
i.e.,in 2 divided doses
i.e.,in labeling
i.e.,interval prolongation
i.e.,Inpatients
i.e.,in special populations
i.e.,intended dosing schedule
i.e.,in tolerance
i.e.,insufficiency should be conservative
i.e.,insufficiency.Longer infusions
i.e.,infections
i.e.,inducers of CYP3A4
i.e.,increased risk of bleeding
i.e.,interaction
i.e.,in serum
i.e.,is approximately 1%
i.e.,is elevation of chylomicrons
i.e.,in the study cited
i.e.,Infections:
i.e.,post-ictus neurological condition
i.e.,in mental capacity
i.e.,is recognized
i.e.,in transaminase values
i.e.,induce seizures
i.e.,Initiate conventional therapy
i.e.,in  vertebrates
i.e.,indicated
i.e.,in a frozen state
i.e.,in the elderly
i.e.,increased risk of osteoporosis
i.e.,interfere with antihypertensive  drugs
i.e.,in children and  adolescents
i.e.,in children and adolescents
i.e.,in this respect
i.e.,in vertebrates
i.e.,inducers of CYP3 A4
i.e.,including delayed fetal development
i.e.,impaired renal function
i.e.,incidence
I.M.,Intramuscular
I.M.,present.Intramuscular
i.p.,intraperitoneally
I.V.,intravenous
I.V./P.O.,involving more than 750 patients treated with azithromycin
IAA,indole acetic acid
IAA,indole  acetic acid
IABP,intra-aortic
IBDQ,inflammatory bowel disease questionnaire
IBS,irritable bowel syndrome
IBW,ideal body weight
ICH,intracranial hemorrhage
ICP,intracranial pressure
ICSI,intracytoplasmic sperm injection
ICSI,intra-cytoplasmic sperm injection
ICU,Intensive Care Unit
ICU,pressure.Intensive Care Unit
IDEAL,Incremental Decrease in Endpoints through Aggressive Lipid Lowering Study
IDEAL,Incremental Decrease in Endpoints through  Aggressive Lipid Lowering Study
IDEAL,Incremental Decrease in Endpoints Through Aggressive  Lipid Lowering Study
IDEAL,Incremental Decrease in Endpoints Through Aggressive Lipid Lowering  Study
IDL,intermediate density lipoprotein
IDL,intermediate-density  lipoprotein
IDL,intermediate-density lipoproteins
IDL-C,intermediate density lipoprotein  cholesterol
IDL-C,intermediate density lipoprotein cholesterol
IDLs,intermediate density lipoproteins
IDNT,Irbesartan Diabetic Nephropathy Trial
IDR,idarubicin
ie,infrequently
ie,in serum glucose
ie,its active metabolites
ie,interphalangeal joints
ie,improvement
ie,in 2 divided doses
ie,Initiate conventional therapy
ie,increased risk of osteoporosis
ie,in children and adolescents
ie,incidence
IEF,Isoelectric focusing
IES,Impact of Event Scale
IET,Intradermal endpoint titration
IF-,immunofixation test
IF+,immunofixation
IFIS,Intraoperative Floppy Iris Syndrome
IFN ?-2b,Interferon alfa-2b recombinant
IFN??2a,interferon alfa 2a
IGA,Investigator's Global Assessment
IgE,immunoglobulin E
IGF-1,insulin growth factor-1
IGF-I,Insulin-like Growth  Factor-I/Somatomedin C
IGF-I,insulin-like growth factor I
IgG,immunoglobulin G
IGIV,immune globulin intravenous
IGSC,Immune Globulin Subcutaneous
IGSS,Investigator’s Global Severity Score
IHPS,infantile hypertrophic pyloric stenosis
IHSS,Idiopathic Hypertrophic Subaortic Stenosis
ii,in the dihydrobenzofuran ring;
II,Intravenous Fat Emulsion
III,initial bleed
IL-1,interleukin-1
IL-2,interleukin-2
ILD,interstitial lung disease
IM,intramuscular
IM,intra-muscularly
IM,Intramuscular Solution
IM,intramuscular route
IM,intramuscularly
IMDH,Inosine monophosphate dehydrogenase
IMID,imidazolidinyl urea
Impairment,impairment (creatinine clearance 30 to 70 mL/min/1.73 m2).2
IMPDH,inosine monophosphate dehydrogenase
IMT,intimalmedial thickness
IMT,intimal-medial thickness
INCAT,Inflammatory Neuropathy Cause and Treatment
induction,initial dose of rocuronium bromide injection under sevoflurane
Inhibitors,inhibitors
Injection,injection
Injection,injection] aqueous
Injection,injectable suspension
Injection,Injectable Emulsion
Injection;,Injection USP 3%
INR,international normalized ratio
INR,Interactions                             sections
INR,International Normalized  Ratio
INR,International  Normalized Ratio
INR,international normalization ratio
INRW,INR for warfarin alone
INRW,INR on warfarin alone
INRW,INR value on warfarin alone
INRWA,INR for co-therapy of warfarin and argatroban
Iodide,iodine- containing Radiographic contrast agents
IOM,Institute of Medicine
IONSYS™,iontophoretic transdermal system
IOP,intraocular pressure
IOP,intraocular  pressure
IP,intraperitoneal
IPPB,intermittent positive-pressure breathing
IPPB,intermittent positive pressure breathing apparatus
IPPB,intermittent positive pressure breathing
IPSC,Independent Pediatric Safety Committee
IPSS,International Prostate Symptom Score
iPTH,intact parathyroid                                             hormone
iPTH,intact PTH
IQ,Inhibitory Quotient
IR,immediate-release
IR,immediate release
IRC,independent review committee
IRF,immediate-release formulation
IRI,Immunoreactive Insulin
IRIS study,interim analysis of an ongoing study
IRLS scale,International RLS Rating Scale
Iron,iron complex
Iron,iron protein succinylate
ISA,in animals with minimal beta1-agonist
ISA,intrinsic sympathomimetic activity
ISDN,isosorbide dinitrate
ISH,isolated systolic hypertension
ISMN,Isosorbide Mononitrate
Ismo®,isosorbide mononitrate
ISS,Idiopathic short stature
ISS,international staging system
IT,intrathecal
IT,intrathecally
iTNSS,instantaneous scoring
iTNSS,instantaneous total nasal symptom score
ITT,intention-to-treat
ITT,intent-to-treat
ITT,intention to treat
ITT,intent to treat
ITTB,intent-to-treat bacteriological
ITTC,intent-to-treat clinical
IU,IU/kg
IU,international units
IU,International Unit
IUPAC,International Union of Pure and Applied Chemistry
IUS,intrauterine system
IV,intravenous
IV,intravenous infusion
IV,intravenously
IV,"increase</td></tr> <tr valign=""top""><td>Isoproterenol"
IVF,in vitro fertilization
IVF,in vitro fertilization therapy
IVF,in-vitro fertilization
IVF,in  vitro fertilization
IVH,intraventricular hemorrhage
IVIG,intravenous immunoglobulin
IWG,International Working Group
J/cm,300 Joules/cm
Jasmine,Jasminum Officinale
Jaundice,jaundice
JIA,juvenile idiopathic arthritis
JME,Juvenile Myoclonic Epilepsy
JRA,Juvenile Rheumatoid Arthritis
JRA,2.4??Juvenile Rheumatoid Arthritis
JRS,Jankovic Rating Scale
JSN,Joint Space Narrowing
July,J: Urology 10:23-24
KAPS,Kuopio Atherosclerosis Prevention Study
kcal,kilocalories
KCS,Keratoconjunctivitis sicca
kg,kilograms
KGF,Keratinocyte growth factor
KIU,Kallikrein Inhibitor Units
kJ,kilojoules
KOOS,Knee Injury and Osteoarthritis Outcome Score
KPS,"Rrule"">Karnofsky Performance Status"
KPS,Karnofsky Performance Status
KS,Kaposi’s sarcoma
KS,Kaposi's sarcoma
L/hr,L/hr/kg
L/min,"align=""left"" valign=""top"">Increase in Morning Peak <br/>Flow Rate"
LAAM,levo-alpha-acetyl-methadol
LADs,Luer-Activated Devices
LAIV,aspirin.Live Attenuated Influenza Vaccine
LAIV,Live Attenuated Influenza Vaccine
LATUDA,LATUDA-treated patients versus placebo for the BAS
lb,"Lrule Rrule""> Patient<br/>weight"
lb.,<td>Lean Body Mass
lb.,<br/>&#160;&#160;&#160;&#160;Lean Body Mass
LBM,Lean body mass
LCAS,Lipoprotein and Coronary Atherosclerosis Study
LCIS,lobular carcinoma in situ
LD,loading dose
LDH,lactic dehydrogenase
LDH,lactate dehydrogenase
LDL,low density lipoprotein
LDL,low-density lipoprotein
LDL-C,low-density lipoprotein cholesterol
LDL-C,low density lipoprotein cholesterol
LDL-C,LDL-cholesterol
LDL-C,low-density lipoprotein                 cholesterol
LDLs,low density lipoproteins
L-dopa,levodopa
LDPE,low density polyethylene
LDPE,low-density polyethylene
LE,lupus erythematosus
LES,lower esophageal sphincter
LESP,lower esophageal sphincter pressure
LESP,lower  esophageal sphincter pressure
LEVONEST™,levonorgestrel and ethinyl estradiol tablets–triphasic regimen
LEVONEST™,levonorgestrel and ethinyl estradiol tablets—triphasic regimen
LFT,liver function tests
LFT,liver functiontests
LFTs,liver function tests
LGD,low-grade dysplasia
LGS,Lennox-Gastaut syndrome
LH,luteinizing hormone
LH,luteinizing  hormone
LIFE,Losartan Intervention For Endpoint reduction in hypertension
LIPID,Long-term Intervention with Pravastatin in Ischemic Disease
LLPDD,Luteal Phase Dysphoric Disorder
LMA,laryngeal mask airway
LMWH,low molecular weight heparin
LNG,levonorgestrel
LOCF,last observation carried forward
LOCF,last reported day was carried  forward
logP,log partition coefficient
LOQ,limit of quantitation
lorazepam,Lorazepam
LPS,latency to persistent sleep
LS,least-square
LSAS,Liebowitz Social Anxiety Scale
LSAS,Liebowitz Social Anxiety  Scale
LTs,leukotrienes
Lupus,lupus erythematosus
LV,leucovorin
LV,left ventricle
LV,left  ventricle
LVD,left ventricular dysfunction
LVEDP,left ventricular end-diastolic pressure
LVEDP,left ventricular  end diastolic pressure
LVEDP,left ventricular end diastolic pressure
LVEF,left ventricular ejection fraction
LVH,left ventricular hypertrophy
LVIDD,left ventricular internal diastolic diameter
M-1,model.11A pentapeptide
M3G,morphine-3-glucuronide
M6G,morphine-6-glucuronide
MA,megestrol acetate
MAA,Monotherapy Arms Analysis
Maalox®,Maalox administration.Antacid
MAC,Monitored Anesthesia Care
MAC,Mycobacterium avium complex
MAC,minimum alveolar concentration
MAC,Mycobacterium avium  complex
MAC,Mycobacterium avium                    Complex
MAC,Mycobacterium avium                          Complex
MAC,MycobacteriaMycobacteriaMycobacterium avium complex
MAC,of:Mycobacterium avium complex
MAC,infection.Mycobacterium avium complex
MAC,Mycobacterium  avium complex
MADRS,Montgomery and Asberg Depression Rating Scale
MADRS,Montgomery and  Asberg Depression Rating Scale
MADRS,Montgomery-Asberg Depression Rating Scale
MADRS,Montgomery Asberg Depression Rating Scale
Magnesium,magnesium oxide
magnesium,Magnesium Sulfate
MaHR,major hematologic response
male,"valign=""middle"">&#160;</td>                                           </tr>                                           <tr>                                              <td>&#160;&#160;&#160;Abnormal Ejaculation"
mA-min,milliampere-minutes
MAO,monoamine oxidase
MAO,Maximum acid output
MAO,depression.Monoamine oxidase
MAO,of:Monoamine oxidase
MAO,observation.Monoamine Oxidase
MAO,may be needed.OthersOthersMonoamine Oxidase
MAO,inhibitors;Monoamine oxidase
MAO,recommended.Monoamine oxidase
MAO,monoamine  oxidase
MAOI,monoamine oxidase inhibitors
MAOI,monoamine oxidase inhibitor
MAOI,monoamine oxidase
MAOI,Monoamine Oxidase  Inhibitor
MAOI,caution.Monoamine oxidase inhibitors
MAOI,concomitantly.Monoamine oxidase inhibitors
MAOI,Solution.Monoamine Oxidase Inhibitors
MAOIs,monoamine oxidase inhibitors
MAOIs,inhibited.Monoamine Oxidase Inhibitors
MAOIs,treatment.Monoamine Oxidase Inhibitors
MAOIs,recommended.Monoamine Oxidase Inhibitors
MAOI's,monoamine oxidase inhibitors
MAOs,Monoamine oxidase inhibitors
MAP,mean arterial blood pressure
MAP,Mean Arterial Pressure
MAP,mean airway pressure
MAP,mean arterial                                     pressure
MARS,Monitored Atherosclerosis Regression Study
MAS,macrophage activation syndrome
MBC,minimum bactericidal concentration
MBC,minimum bactericidal concentrations
MBC,minimal bactericidal concentration
MBC/MIC,minimum bactericidal concentration/minimum inhibitory concentration
MBCs,minimum bactericidal concentrations
MBL,menstrual blood loss
MBq,megabecquerel
MC,molluscum contagiosum
MCE,major coronary events
mcg,micrograms
mcg/kg,"styleCode=""bold"">(mcg/kg/min)  </content></td><td align=""center""><content styleCode=""bold"">Supplemental IV Bolus Dose of</content><br/><content styleCode=""bold"">ULTIVA"
mcg/kg,"<br/>(mcg/kg/min)</content></td><td align=""center""><content styleCode=""bold"">Supplemental IV             <br/>Bolus Dose of             <br/>ULTIVA"
mcg/mL,"underline"">Microorganism</content>                                                 </content>                                              </td>                                              <td align=""center"">                                                 <content styleCode=""bold"">                                                    <content styleCode=""bold underline"">MIC"
mcg/mL,MicroorganismsAntimicrobialMIC
mCi,millicurie
MCI,mild cognitive impairment
mCPP,m-chlorophenylpiperazine
mCPP,meta-chlorophenylpiperazine
MCS,Mental Component Summary
MCV,Mean Cell Volume
MCVE,major cardiovascular events
MCyR,major cytogenetic response
MDBGN,methyldibromo glutaronitrile
MDD,major depressive disorder
MDD,major  depressive disorder
MDD,major depressive disorcer
MDD,1.2)Major Depressive Disorder
MDG,mean daily glucose
MDRD,Modification of Diet in Renal Disease
MDRSP,multi-drug resistant Streptococcus pneumoniae
MDRSP*,multi-drug resistant Streptococcus pneumoniae
MDRTB,Multi-Drug Resistant Tuberculosis
MDRTB,Multi-Drug Resistant  Tuberculosis
MDS,myelodysplastic syndrome
MDS,myelodysplastic syndromes
ME,microbiologically evaluable
mean,men between the ages of 38 and 91
mean,men between the ages of 31 and 87
Mean,mean age 32 years (range 23-59 years
mean age,minutes to 9 pediatric cancer patients receiving chemotherapy
mean age,minutes to nine pediatric cancer patients  receiving chemotherapy
mean age,minutes
mean age,minutes to nine pediatric cancer patients receiving chemotherapy
mean dose,mean baseline requirements included beclomethasone dipropionate
MEC,Moderately Emetogenic Chemotherapy
MEC,moderately emetogenic cancer chemotherapy
MED,minimum erythematous dose
MED,Minimal Erythema Dose
MedDRA,Medical Dictionary for Regulatory Activities
MedDRA,Medical Dictionary for Regulatory Activities terminology
MedDRA’s,Medical Dictionary for Regulatory Activities
MEDWATCH,www.fda.gov/medwatch
MEF,Middle-ear fluid
MEF,middle ear fluid
MEGX,monoethylglycinexylidide
MEGX,mono-ethylglyciniexylidide
mEq/day,mEq three times/day with meals
MES,maximal electroshock seizure
MES,maximal  electroshock seizure
MES,maximum electroshock
Met,Metformin
Met,Metformin Hydrochloride
MET,Metformin Hydrochloride Tablets
METEOR,Media Thickness: an Evaluation Of Rosuvastatin 40 mg
METROGEL®,metronidazole topical gel
MEXITIL,mexiletine hydrochloride
MEXITIL®,mexiletine hydrochloride
MFSAF,Myelofibrosis Symptom Assessment Form
mg/day,mg/dayTopiramate Group Topiramate Dosage
mg/dL,mg Once DailyTotal Cholesterol
mg/dL,<td>Met<br/>Vs Glyb<br/>                            </td>                         </tr>                         <tr>                            <td>Fasting Plasma<br/>Glucose
mg/dL,mg Twice DailyPlaceboTotal Cholesterol
mg/dL,mg  Twice  DailyPlaceboTotal Cholesterol
mg/kg/day,mg/kg/day: Daily dose
mg/kg/day,mg/kg/day:                                                Daily dose
mg/kg/day,mg/kg/day:                                                                          Daily dose
mg/kg/day,mg/kg/day:                                                                                                    Daily dose
mg/kg/day,mg/kg/day:                                                                            Daily dose
mg/kg/day,mg/kg/day:                                                                                       Daily dose
mg/kg/day,mg/kg/day:                                                                      Daily dose
mg/kg/day,mg/kg/day:                                        Daily dose
mg/kg/day,mg/kg/day:                                                                  Daily dose
mg/kg/day,mg/kg/day:                   Daily dose
mg/kg/day,mg/kg/day:                                                                                       Daily dose
mg/kg/day,mg/kg/day:                                                                       Daily dose
mg/kg/day,mg/kg/day:                                                                                                                    Daily dose
mg/kg/day,mg/kg/day:                                                                                  Daily dose
mg/mL,mg/5 mL
mg/mL,mg in 100 mL
mg/mL,mg in 100 mL
mg/mL,mg of anhydrous tacrolimus per mL
Mg++,magnesium
mGy,milligray
MH,Malignant Hyperthermia
MHAQ,[Modified Health Assessment Questionnaire
MHD,10-monohydroxy metabolite
MHPG,3-methoxy- 4-hydroxyphenyl glycol
MI,myocardial infarction
MI,myocardial  infarction
M-I,metabolite
MIC,minimum inhibitory concentration
MIC,minimal inhibitory concentration
MIC,minimum inhibitory  concentration
MIC,minimum  inhibitory concentration
MIC,minimum inhibitory concentrations
MIC,minimum inhibitory                         concentration
MIC,minimal  inhibitory concentration
MIC,more of the following antibiotics: penicillin
MIC’s,minimal inhibitory concentrations
MIC’s,minimum inhibitory concentrations
Mice,Micronucleus Test
Mice, Micronucleus Test
Mice,   Micronucleus Test
Mice,Assay Micronucleus Test
mice,maximum recommended human doses are 400
MICs,minimum inhibitory concentrations
MICs,minimal inhibitory concentrations
MICs,minimum
MICs,minimum  inhibitory concentrations
MICs,minimum inhibitory  concentrations
MICs,minimal inhibitory  concentrations
MICs,minimal  inhibitory concentrations
MIC's,minimal inhibitory concentrations
MIC's,minimum  inhibitory concentrations
MIC's,minimum inhibitory concentrations
MIC's,minimal inhibitory  concentrations
MIHA,m-iodohippuric acid
min,"Rrule"">T<sub>max</sub><footnote>Time-to-peak plasma concentration</footnote>"
min,median
min,"Botrule"">Median"
min,"Botrule"">Median % Change"
min,Median % Change
min,<th>Median
min,"colspan=""2"">Median % Change"
min,Median Percent Change
min,"valign=""middle""><paragraph>Median time to first</paragraph><paragraph>emetic episode"
min,"align=""center"">Median"
min,"align=""center"">Median % Change"
min,"valign=""top"">&#160;&#160;&#160;&#160;Median"
MINI,Mini-International Neuropsychiatric  Interview
MINOCIN®,minocycline hydrochloride
MINOCIN®,minocycline
MIRD,Medical Internal Radiation Dose
MIT,monoiodotyrosine
MITT,modified Intent-to-Treat
MIU,million international units
mL,milliliter
mL,mg phospholipids
mL,mg dalteparin sodium
mL,mEq/L
mL,milliliters
mL,Maintenance Dose for diluents
mL,Maintenance Dose                             for diluents
mL,may be calculated: Dose
mL,mg tablet
mL,mg of lidocaine HCl
mL,mg prednisolone base
mL,mg lidocaine HCl
mL,mg vial
mL,MAINTENANCE DOSE for                             diluents
mL,mL/kg
mL,mEq/liter
mL/day,mg/kg/day:                         Total daily dose
mL/day,mg/kg/day:                               Total daily dose
mL/kg,meglumine/kg
mL/min,"valign=""middle"">Percent of dose excreted in urine</td><td align=""center"" styleCode=""Botrule"" valign=""middle"">Total Clearance"
mL/min,may be used to estimate creatinine clearance:                         Men: Creatinine clearance
mL/min,may be used to estimate creatinine clearance:Men: Creatinine clearance
MLD,minimum lumen diameter
MLD,minimum lethal dose
mm,MicroorganismZone Diameter
mm,Microorganism Zone Diameter
mm,strains:Microorganism Zone Diameter
mm,MicroorganismZone Diameter Ranges
MMC,mitomycin C
MMEF,maximal midexpiratory flow rate
MMEF,maximum midexpiratory flow rate
MMF,mycophenolate mofetil
MMF,Prograf/mycophenolate mofetil
mmHg,maximal change in baseline in systolic blood pressure
mmHg,maximal change from baseline in systolic blood pressure
mmol/L,monoxide associated with smoke inhalation also contributes to lactic acidemia
MMPs,matrix metalloproteinases
MMSE,Mini-Mental State Examination
MN,mononuclear
Mn,manganese
MNA,mouse neutralization assay
MNA,N-methylnicotinamide
MNW,mean number of wheals
MNW,mean  number of wheals
Moderate,moderately darker than the surrounding normal skin
MOF,multiple organ failure
moniliasis,MONISTAT 3 Vaginal Suppositories are indicated for the local treatment of vulvovaginal candidiasis
MO-TMS,methoxime-trimethylsilyl
MO-TMS,methoximetrimethylsilyl
mouse,maleate was devoid of mutagenic potential when tested invivo
mouse,maleate was devoid of mutagenic potential when tested in vivo
MP,methylprednisolone
MPA,medroxyprogesterone acetate
MPA,medroxyprogesterone  acetate
MPA,mycophenolic acid
MPA,Microscopic Polyangiitis
mPAP,mean pulmonary artery pressure
MPEG,methoxypolyethylene glycol
MPEG-DSPE,N-(carbonyl-methoxypolyethylene glycol 2000)-1
MPF,Methyl Paraben Free
MPH,methylphenidate
MPM,Malignant Pleural Mesothelioma
MPS,mean pruritus scores
MPS,mononuclear phagocyte system
MPS,mean pruritus score
MPTP,1-methyl-4-phenyl-1
MQA,monoquaternary alcohol
MRA,magnetic resonance angiography
mRCC,14.4   Metastatic Renal Cell Carcinoma
MRD,maximum recommended dose
MRDD,maximum recommended daily dose
MRDHD,maximum recommended daily human dose
MRDHD,maximum recommended daily human oral dose
MRHD,maximum recommended human oral daily dose
MRHD,maximum recommended human dose
MRHD,maximum  recommended human daily dose
MRHD,maximum recommended human dose 
MRHD,*Maximum recommended human dose
MRHD,maximum recommended daily human dose
MRHD,Maximum  Recommended Human Dose
MRHD,maximum recommended human daily dose
MRHD,maximum recommended  human dose
MRHD,maximum recommended daily human oral dose
MRHD,maximum recommend human dose
MRHD,maximum  recommended daily human oral dose
MRHD,maximum recommended human daily  dose
MRHD,maximum recommended human daily
MRHD,Maximum Recommended Human  Dose
MRHD,m*Maximum recommended human dose
MRHD,maximum recommended human dose for schizophrenia
MRHDD,maximum recommended human daily dose
MRHDD,maximum recommended  human daily dose
MRHDID,maximum recommended human daily inhalation dose
MRHTD,maximum recommended human topical dose
MRI,magnetic resonance imaging
MRI,Magnetic Resonance Imaging scan
MROHD,maximum recommended ocular human dose
MROHD,maximum recommended ocular human dose of 0.0014 mg/kg/day
MROHD,maximum  recommended ocular human dose
MRP-2,multidrug-resistance-associated protein 2
MRS,Manic Rating Scale
MRS,Manic  Rating Scale
MRS,Mania Rating Scale
MRSA,methicillin-resistant staphylococci
MRSA,methicillin-resistant Staphylococcus aureus
MRT,mean residence time
MS,Multiple Sclerosis
MSDS,Material Safety Data Sheet
msec,mseconds
msec,milliseconds
MSKCC,Memorial Sloan Kettering Cancer Center
MSLT,Multiple Sleep Latency Test
MSS,Manic Syndrome Scale
MSVS,moderate to severe vasomotor symptoms
MTC,medullary thyroid cancer
MTD,maximum tolerated dose
MTD,maximally tolerated dose
MTHD,maximum topical human dose
MTHFR,5
MTHFR,
MTIC,5-(3-methyltriazen-1-yl)-imidazole-4-carboxamide
MTOPS,Medical Therapy of Prostatic Symptoms
MTPs,minimally treated patients
MTSS,mean total symptom scores
MTSS,mean total symptom score
mTSS,modified Total Sharp Score
MTX,methotrexate
MTX,"valign=""top""><td>Methotrexate"
MTZ,metronidazole
mU,milliunits
MUGA,multi-gated radionuclide angiography
MUGA,multigated nuclear medicine
MVE,major vascular events
N/593,N over bisect 593
N/596,N over bisect 596
N/598,N over bisect 598
n=11,"Botrule"">1.8<br/>(&#177;1.3)<br/>(n=11)<br/>                                        </td>                                        <td styleCode=""Lrule Botrule"">11.5<br/>(&#177;6.8)<br/>"
n=129,"Botrule"">0.80<br/>(&#177;0.36)<br/>(n=129)</td>                                        <td styleCode=""Lrule Botrule"">24.5<br/>(&#177;9.5)<br/>"
n=20,"Botrule"">1.15<br/>(&#177;0.432)<br/>(n=20)<br/>                                        </td>                                        <td styleCode=""Lrule Botrule"">13.1<br/>(&#177;6.76)<br/>"
n=22,"Botrule"">1.50<br/>(&#177;0.517)<br/>(n=22)<br/>                                        </td>                                        <td styleCode=""Lrule Botrule"">17.0<br/>(&#177;12.7)<br/>"
n=23,"Botrule"">0.90<br/>(&#177;0.24)<br/>(n=23)<br/>                                        </td>                                        <td styleCode=""Lrule Botrule"">24.1<br/>(&#177;12.1)<br/>"
n=25,"Botrule"">1.31<br/>(&#177;0.76)<br/>(n=25)<br/>                                        </td>                                        <td styleCode=""Lrule Botrule"">8.16<br/>(&#177;4.50)<br/>"
n=27,"Botrule"">1.21<br/>(&#177;0.81)<br/>(n=27)<br/>                                        </td>                                        <td styleCode=""Lrule Botrule"">13.5<br/>(&#177;8.18)<br/>"
n=31,"Botrule"">1.33<br/>(&#177;1.05)<br/>(n=31)<br/>                                        </td>                                        <td styleCode=""Lrule Botrule"">10.7<br/>(&#177;4.83)<br/>"
n=31,"Botrule"">1.58<br/>(&#177;0.46)<br/>(n=31)<br/>                                        </td>                                        <td styleCode=""Lrule Botrule"">12.0<br/>(&#177;3.82)<br/>"
N=496,<td>&#160;PLACEBO<br/>(N=496)<br/>                            </td>                            <td>&#160;PLACEBO<br/>
n=52,"Botrule"">1.1<br/>(&#177;0.7)<br/>(n=52)<br/>                                        </td>                                        <td styleCode=""Lrule Botrule"">20.0<br/>(&#177;9.4)<br/>"
NA,<td>Not applicable
NAAED,North American Antiepileptic Drug
NAAED,NorthAmerican Antiepileptic Drug
NAAED,North American Antiepileptic  Drug
NAAED,North American  Antiepileptic Drug
NAC,N-acetylcysteine
N-Ac-5-ASA,N-acetyl-5-aminosalicylic acid
NAD,N-acetyl-dapsone
NAION,Non-arteritic anterior ischemic optic neuropathy
NAPA,N-acetylprocainamide
NAPQI,N-acetyl-p-benzoquinone imine
NAPR,nonallergic perennial rhinitis
NAPRTCS,North American Pediatric Renal Transplant Cooperative
NAT,nucleic acid testing
NAT,Nucleic Acid Test
NATO,Nolvadex Adjuvant Trial Organization
NCCLS,National Committee for Clinical Laboratory Standards
NCCTG,North Central Cancer Treatment Group
NCEP,National Cholesterol Education Program
NCGS,National Cooperative Gallstone Study
NCI,National Cancer Institute
NCI CTC,National Cancer Institute Common Toxicity Criteria
nCR,Near complete response
ND,NDMinor Bleedingd391031333.21a
NE,norepinephrine
NE,neuroendocrine
NEL,no evidence of leukemia
NET,norethindrone
NFIS,Nine Face Integrated Scale
NFV,nelfinavir
ng/mL,ng/ml
NGU,Nongonococcal urethritis
NGU,days.Nongonococcal urethritis
NHL,14.2 Non-Hodgkin Lymphoma
NHL,non-Hodgkin's lymphoma
niacin,Niacinaminde
NIC,nicardipine
NIDDM,non-insulin-dependent diabetes mellitus
NIHSS,National Institutes of Health Stroke Scale
NIOSH,National Institute for Occupational Safety and Health Administration
NIOSH,National Institute of Occupational Safety and Health
NK,natural killer
NLT,not less than
NMDA,N-methyl-D-aspartate
NMDA,N-methyl d-aspartate
NMP,N-methylpyrrolidine
NMS,neuroleptic malignant syndrome
NMS,Neuroleptic Malignant  Syndrome
NMS,Neuroleptic  Malignant Syndrome
NMT,not more than
NNO,nicotinamide-N-oxide
NNRTI,non-nucleoside reverse transcriptase inhibitor
NNRTI,non-nucleoside reverse transcriptase inhibitors
NNRTIs,Non-Nucleoside Reverse Transcriptase Inhibitors
NNRTIs,"styleCode=""italics"">Non-nucleoside Reverse Transcriptase Inhibitors"
NO,nitric oxide
NOAEL,no observed adverse effect level
NOAEL,no-observed-adverse-effect-level
NOAEL,no adverse effect level
NOAEL,no-adverse effect levels
NOAEL,no observable adverse effect level
NODAT,New Onset Diabetes After Transplant
NOEL,no-observed-effect-level
NOEL,noobserved-effect level
NOEL,no-observed-effect level
none,nauseaSeverity of nausea
non-HDL-C,non-high-density lipoprotein cholesterol
NOS,not otherwise specified
NOTEL,“No Observable Teratogenic Effects Level”
NPCP,National Prostate Cancer Project
NPN,non-protein nitrogen
NPN,nonprotein nitrogen
NRS,numerical rating scale
NRTIs,nucleoside reverse transcriptase inhibitors
NRTIs,nucleoside reverse transcriptase  inhibitors
NRTIs,nucleoside/nucleotide reverse transcriptase inhibitors
NSAID,nonsteroidal anti-inflammatory drug
NSAID,nonsteroidal                                 anti-inflammatory drug
NSAID,non-steroidal anti-inflammatory drug
NSAID,NSAIDs that inhibit both cyclooxygenase isoenzymes
NSAIDs,nonsteroidal anti-inflammatory drugs
NSAIDs,nonsteroidal antiinflammatory drugs
NSAIDs,non-steroidal anti-inflammatory drugs
NSAIDs,nonsteroidal                                         anti-inflammatory drugs
NSAIDs,non steroidal anti-inflammatory drugs
NSAIDs,NONSTEROIDAL  ANTI-INFLAMMATORY DRUGS
NSAIDs,nonsteroidal                                 anti-inflammatory drugs
NSAIDs,nonsteroidal                             anti-inflammatory drugs
NSAIDs,function.Nonsteroidal Anti-Inflammatory Drugs
NSAIDs,Aspirin/Nonsteroidal Anti-Inflammatory Drugs
NSAIDs,Non- Steroidal Anti-Inflammatory Drugs
NSAIDs,Non-Steroidal  Anti-Inflammatory Drugs
NSAIDS,Non-Steroidal Anti-Inflammatory DrugsNonsteroidal anti-inflammatory drugs
NSAIDs,     Non-Steroidal Anti-Inflammatory Drugs
NSAIDs,Nonsteroidal                          Anti-inflammatory Dr                         ugs
NSAID's,Nonsteroidal Anti-inflammatory Drugs
NSCLC,Non-Small Cell Lung Cancer
NSCLC,Non?Small Cell Lung Cancer
NSCLC,Non-Small Cell Lung Carcinoma
NSCLC,non-small-cell lung cancer
NSF,NEPHROGENIC SYSTEMIC FIBROSIS
NST,nonstress test
NSTEMI,/non-ST-elevation myocardial infarction
NSTs,nonstress tests
NSVT,non-sustained ventricular tachycardia
NTD,neural tube defects
NTD's,Neural tube defects
NTG,nitroglycerin
NTP,National Toxicology Program
NTPR,National Transplantation Pregnancy Registry
NTS,nicotine transdermal system
NTS,nicotine  transdermal system
NUA,nicotinuric acid
NVP,nevirapine
NWS,neonatal withdrawal syndrome
NWS,neonatal withdrawal  syndrome
NYHA,New York Heart Association
NYHA,New York Heart  Association
OA,osteoarthritis
OA,oral agents
OAB,overactive bladder
OADC,oleic acid-albumin dextrose-catalase
OADC,oleic acid-albumin-dextrose-catalase
OADC,oleic  acid-albumin-dextrose-catalase
OAT3,organic anion transporter 3
OBR,optimized background regimen
OBT,optimized background therapy
OC,oral contraceptive
OCAS,Ordered Category Anesthesia Scale
OCD,obsessive compulsive disorder
OCD,obsessive  compulsive disorder
OCD,obsessive complusive disorder
OCD,Obsessive-Compulsive Disorder
OCD,obsessive compulsive  disorder
OCT,organic cationic transporter
OD/uL,optical density units per uL
ODC,ornithine decarboxylase
ODV,O-desmethylvenlafaxine
ODV,O-desmethyl venlafaxine
ODV,O–desvenlafaxine
ODV,O-desvenlafaxine
ODV,O?desmethylvenlafaxine
ODV,of venlafaxine and its active metabolite
OGTT,oral glucose tolerance test
OHSS,ovarian hyperstimulation syndrome
OI,osteogenesis imperfecta
Oil,oil
Ointment,ointment
OND,ondansetron
one patient,of >3.5 x ULN occurred in 0.1% of patients taking TEVETEN®
one tablet,of ketoconazole tablets is a single daily administration of 200 mg
ONJ,Osteonecrosis of the jaw
only,ondansetron was administered intravenously
only,ondansetron injection was administered intravenously
OPHTHALMIC®,ophthalmic solution
OR,Operating Room
or delegate,of wholesaler records for verification of compliance with the iPLEDGE program by the isotretinoin manufacturer
oral,oralAsparaginasecontraceptivesGlucocorticoidsEstrogens
ORR,objective response rate
ORR,Overall response rate
OS,overall survival
OTC,over-the-counter
OTPs,Opioid Treatment Programs
overwrap,of Abbott ADD-Vantage containers following removal of the outer packaging
oxine,oxyquinoline
oxytocin,or 5% dextrose in physiologic saline solution to which 10 units of Syntocinon®
p.c.,post coitum
p.p.,post-partum
p.p.,postpartum
P.P.I.,Patient Package Insert
PA,Procainamide
PAAS,Panic and Anticipatory Anxiety Scale
PABA,para-aminobenzoic acid
PACTG,Pediatric AIDS Clinical Trials Group
PACU,post anesthesia care unit
PAD,peripheral arterial disease
PAF,paroxysmal atrial fibrillation/flutter
PAF,[paroxysmal atrial fibrillation/flutter
PAF,platelet activating factor
PAF,paroxysmal AF
PAH,pulmonary arterial hypertension
PAH,pulmonary hypertension
PANSS,Positive and Negative Symptoms Scale
PANSS,Positive and Negative Syndrome  Scale
PANSS,Positive and Negative Syndrome Scale
PANSS,Positive and  Negative Syndrome Scale
PAP,pulmonary arterial pressure
PAP,photoactive porphyrins
PAP,pulmonary artery pressure
PARS,Pediatric Anxiety Rating Scale
Part  I,4-part multi-item rating scale intended to evaluate mentation
Part I,4-part multi-item rating scale intended to evaluate mentation
Part I,posttreatment for success in treating early Lyme disease
part I,four-part multi-item rating scale intended to evaluate mentation
PAS,para-aminosalicylic acid
PASI,Psoriasis Area and Severity Index
PASI 75,PASI score of at least 75%
Patients,patients
Patients,Patient Package Insert
Patients,Patient Package  Insert
Patients,patient is incompetent
Patients,package insertpatient package insert)
PB,pulmonary embolism
PB,"valign=""top""><td>Phenobarbital"
PBC,primary biliary cirrhosis
PBI,protein bound iodine
PBI,protein-bound iodine
PBI,affected.Protein-bound iodine
PBI,protein-bound  iodine
PBMCs,peripheral blood mononuclear cells
PBP,penicillin binding proteins
PBP,penicillin-binding-protein
PBP3,penicillin binding protein 3
PBPC,peripheral blood progenitor cell
PBPs,penicillin binding proteins
PBPs,penicillin-binding proteins
PCA,patient-controlled analgesia
PCA,Primary Core Analysis
PCC,Partial Coagulation Complex
PCDAI,Pediatric Crohn's Disease Activity Index
PCI,percutaneous coronary intervention
PCIs,percutaneous coronary interventions
PCOS,polycystic ovary syndrome
PCP,Pneumocystis carinii pneumonia
PCP,Pneumocystis jiroveci pneumonia
PCP,contraindicated.Pneumocystis carinii pneumonia
PCPT,Prostate Cancer Prevention Trial
PCPZ,prochlorperazine
PCR,"styleCode=""italics"">Probable Causal Relationship"
PCR,polymerase chain reaction
PCS,Physical Component Summary
PCT,parasite clearance time
PCWP,pulmonary-capillary wedge pressure
PCWP,pulmonary capillary wedge pressure
PCyR,partial cytogenetic response
PD,pain threshold depth
PD,panic disorder
PD,peritoneal dialysis
PD,pocket depth
PD R,Physicians'Desk Reference
PDD,Photodynamic Diagnostic
PDD,Photodynamic Diagnosis
PDE,phosphodiesterase
PDE5,phosphodiesterase type 5
PDE-5,phosphodiesterase-5
PDR,.Physicians' Desk Reference
PDR,Physicians' Desk Reference
PDR,.Physicians’ Desk Reference
PDR,Physicians’ Desk Reference
PDR,Physicians'Desk Reference
PDR,Physician’s Desk Reference®
PDR,Physicians' Desk Reference®
PDR,patient.Physicians’ Desk Reference
PDR,Physicians’ Desk  Reference
PDR,“Physicians' Desk Reference
PDR,Physician's Desk Reference®
PDR,“Physicians’ Desk Reference
PDR,patient.Physicians' Desk Reference
PDR,Physicians' Desk  Reference
PDR®,Physicians’ Desk Reference®
PDR®,Physicians’ Desk Reference ®
PDR®,Physicians' Desk Reference®
PDS,prefilled dual chamber syringe
PDSS,Panic Disorder Severity Scale
PDT,photodynamic therapy
PDT,verteporfin.Photodynamic therapy
PE,pulmonary embolism
PE,phenoxyethanol
PE,phenytoin sodium equivalents
PE,phenytoin sodium                                                   equivalent units
PE,phenytoin sodium equivalent units
PE,phenytoin sodium                                             equivalent units
PE,pulmonary embolus
PEA,arrest/pulseless electrical activity
PEG,[Polyethylene glycol
PEG,polyethylene glycol
PEG 400,polyethylene glycol 400
Pentoxil®,Pentoxifylline Extended-release Tablets
PEP,post-exposure prophylaxis
Percent,Percentage of Responders at Endpoint                                                                                                                                                                 Difference
Period B,Period A were randomized into the double-blind phase
PES,programmed electrical stimulation
PET,Positron Emission Tomographic
PET,Positron emission  tomographic
PET,polyethylene terephthalate
PET,positron emission tomography
PET,polyethylene  terephthalate
PET,packaged in a clear plastic
PF4,Platelet Factor 4
PFR,peak flow rate
PFS,progression?free survival
PFS,progression-free survival
PFS,progression free survival
PG,prostaglandin
PG,prostagladin
PGA,Physician Global Assessment
PGA,Physician’s Global Assessment
PGA,Physician's Global Assessment
PGE2,prostaglandin E2
PGI,patient global impression of change
Pgp,P-glycoprotein
Pgp,Pglycoprotein
P-gp,P-glycoprotein
PgR,progesterone  receptor
PGTC,primary generalized tonic-clonic
PH,pulmonary hypertension
Ph,Philadelphia chromosome
PH/SSD,Pulmonary Hypertension Associated with the Scleroderma Spectrum of Diseases
Ph+ ALL,Philadelphia chromosome positive acute lymphoblastic leukemia
phenytoin,protein binding sites are therefore unlikely.Potential pharmacokinetic interactions were assessed in clinical pharmacokinetic studies
PHHI,persistent hyperinsulinemic hypoglycemia of infancy
PHN,postherpetic neuralgia
PHN,Post herpetic neuralgia
PI,primary immunodeficiency
PI,primary humoral immunodeficiency
PIC,Polysaccharide iron complex
PID,Pain Intensity Difference
PID,Pain Intensity Differences
PIF,peak inspiratory flow
PIFE,pentafluoroisopropenyl fluoromethyl ether
PIPRACIL®,piperacillin for injection
PIs,protease inhibitors
PK,pharmacokinetic
PK,pharmacokinetics
PK/PD,pharmacokinetic/pharmacodynamic
PKU,phenylketonuria
PKU,phenyketonuria
PLAC I,Pravastatin Limitation of Atherosclerosis in the Coronary Arteries
placebo,placebo-controlled study in 207 patients
placebo,placebo-controlled studies in 629 patients
plague,potentially toxic agents.a.Pasteurella pestis
PLENDIL,prolongation in the half-life of felodipine.Erythromycin—Co-administration of felodipine
PLESS,PROSCAR Long-Term Efficacy and Safety Study
Plus,prednisolone acetate ophthalmic suspension
PM,poor metabolizers
PM,PMs - 38% to 105%
PM,PM's -38% to 105%
PM,PMs -38% to 105%
PM,PMs - 38% to 105%
PMA,postmenstrual age
PMDD,Premenstrual Dysphoric Disorder
PMFE,pentafluoromethoxy isopropyl fluoromethyl ether
PMFE,pentafluromethoxy isopropyl fluoromethyl ether
PML,progressive multifocal leukoencephalopathy
PMN,polymorphonuclear
PMNs,<tr><td/><td>&#8593;Polymorphonuclear neutrophils
PMNs,polymorphonuclear neutrophils
PMs,poor metabolizers
PMs,PMs4% to 134%
PMs,PMs - 4% to 134%
PMs,PMs 4% to 134%
PNH,Paroxysmal Nocturnal Hemoglobinuria
pNP-Glc,para-nitrophenyl-?-D-glucopyranoside
PNS,peripheral  nervous system
PNS,peripheral nervous system
PONV,postoperative nausea and vomiting
Population,Populations
PP,Per-Protocol
PPA,Phenylpropanolamine hydrochloride
PPAA,?-phenyl-piperidine acetic acid
PPAR?,peroxisome proliferator activated receptor ?
PPAR?,peroxisome  proliferator-activated receptor-gamma
PPAR?,peroxisome proliferator receptor alpha
PPARs,peroxisome proliferator activator receptors
PPB,Per  Protocol Bacteriological Population
PPC,per protocol
PPG,post-prandial glucose
PPG,postprandial plasma glucose
PPHN,pulmonary hypertension of the newborn
PPHN,pulmonary  hypertension of the newborn
PPHN,pulmonary  hypertension of the newborn
PPI,pump inhibitors
PPI,pump inhibitor
PPI,Patient Package Insert
PpIX,protoporphyrin IX
PPK,population pharmacokinetic
PR,partial responses
PR,Partial response
PR,partial
PR,<br/>Partial<br/>Response
PR,<br/>Partial Response
PR,2. Pain Relief
PR,Pharma
PR48,PegIntron + REBETOL for 48 weeks
PRA,plasma renin activity
PRA,plasma renin  activity
PRA,panel-reactive antibodies
PRCA,pure red cell aplasia
preload,pressure and pulmonary capillary wedge pressure
preload,pressure and
preload,pressure and pulmonary capillary                             wedge pressure
PRES,posterior reversible encephalopathy syndrome
PRISM,Platelet Receptor Inhibition for Ischemic Syndrome Management
PROactive,Prospective Pioglitazone Clinical Trial In Macrovascular Events
PROactive,Prospective Pioglitazone Clinical  Trial In Macrovascular Events
procaine,persons with known drug sensitivities.  Patients allergic to para-aminobenzoic acid derivatives
prolonged,age;Prophylactic use of Fansidar in pregnancy at term and during the nursing period.Repeated prophylactic
PRSP,Penicillin-resistant S. pneumoniae
PRSP,penicillin-resistant Streptococcus pneumoniae
PS,PERFORMANCE STATUS
PSA,prostate-specific antigen
PSA,prostate specific antigen
PSS,phenotypic susceptibility score
PSVT,paroxysmal supraventricular tachycardia
PSVT,paroxysmal supraventricular tachycardias
PT,prothrombin time
PT,pharmacologic effects
PT,prothrombin                                             time
P-T,placebo to tesamorelin
PTCA,percutaneous transluminal coronary angioplasty
PTCA,percutaneous
PTDM,Post-Transplant Diabetes Mellitus
PTP,Previously Treated Patients
PTSD,Posttraumatic Stress Disorder
PTT,partial thromboplastin time
PTU,Propylthiouracil
PTU,<paragraph>Propylthiouracil
PTU,<br/>Propylthiouracil
PTU,<br/>Lithium<br/>Methimazole<br/>Propylthiouracil
PTZ,pentylenetetrazol
PUP,Previously Untreated Patients
PUP,Previously Untreated                                     Patients
PUPs,previously untreated patients
PUVA,plus ultraviolet A treatment
PVAN,Polyomavirus associated nephropathy
PVC,polyvinylchloride
PVC,polyvinyl chloride
PVCs,premature ventricular contractions
PVD,peripheral vascular disease
PVL,Panton-Valentine Leukocidin
PVL,periventricular leukomalacia
PVP,polyvinylpyrrolidone
PVR,pulmonary vascular resistance
PVR,pulmonary vascular                                     resistance
PWS,Prader-Willi syndrome
PY,patient-years
pyridoxine,Pyridoxine Hydrochloride
q12h,q12hWeightDose
Q-15,Quaternium-15
QC,Quality control
QCA,quantitative coronary angiography
QDR,quantitative digital radiography
QRDRs,Quinolone-Resistance Determining Regions
QRDRs,Quinolone-  Resistance Determining Regions
QTc,QT and mean corrected QT interval
QTc,QT correction
QTcP,QTc based on population correction method
RA,rheumatoid arthritis
RA,refractory anemia
RAC,rabeprazole plus amoxicillin and clarithromycin
RAEB,RA with excess blasts
RAEB-T,RAEB in transformation
RAP,right atrial pressure
RAP,right                                     atrial pressure
rare,Renal Failure
rare,rechallenge of drug after withdrawal due to rash
rare,ReactionsHematologic Reactionsaplastic anemia
RARs,retinoic acid receptors
RARS,RA with ringed sideroblasts
RAS,renin-angiotensin system
rat,rabbits when given in doses 13
rat,rabbits were approximately one-eighth
rat,rabbits given doses up to 2.5 times
Ratio,ratio with/without coadministered drug
rats,rabbits at doses 40  times
rats,rabbits at glimepiride doses 50 times
RBC,red blood cell
RBC,red blood cells
RBCs,red blood cells
RBS,Registry-Based Study
RBS,Registry Based Study
RCC,renal cell carcinoma
RDA,Recommended Dietary Allowance
rDNA,recombinant DNA
RDS,Respiratory Distress Syndrome
RDS,radiologic findings
REA,Restriction Endonuclease Analysis
REACTIONS,reactions are underlined.
rec,recombinant
RECIST,Response Evaluation Criteria in Solid Tumors
Regitine®,regard: Intravenous phentolamine
REGRESS,Regression Growth Evaluation Statin Study
REM,rapid eye movement
REMS,Risk Evaluation and Mitigation Strategy
RENESE,recommended human dose
RES,reticuloendothelial system
RESTORE,Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis
RFD,reference dose
RFID,Radio Frequency Identification
RFS,relapse-free survival
RFS,Recurrence-free survival
RHD,recommended human dose
RHDID,recommended human daily inhalation dose
rhGH,recombinant human GH
rhu GM-CSF,recombinant human granulocyte-macrophage colony stimulating factor
RIA,radioimmunoassay
riboflavin,Riboflavin
RID,radial immunodiffusion
RIP,radio-immunoprecipitation
RLQ,right lower quadrant
RLS,restless legs syndrome
RLS,restless leg syndrome
RLS,restless legs  syndrome
RLS,porphyria
RMA,Risk Management Authorization
RMDQ,Roland-Morris Disability Questionnaire
RMR,rifampin monoresistance
RMT,Royal Marsden Trial
RN,registered Nurse
RNA,ribonucleic acid
RPF,renal plasma flow
rPGA,relative Physician's Global Assessment
RPLS,Reversible Posterior Leukoencephalopathy Syndrome
RPMC,rat pleural mesothelial cells
RPU,renal pelvis ureter
RR,relative risk
RR,risk reductions
RR MS,Relapsing-Remitting Multiple Sclerosis
RRMS,relapsing remitting MS
RSV,respiratory syncytial virus
RT,reverse transcriptase
RT,radiotherapy
rT3,reverse T3
RTA,renal tubular acidosis
rTNSS,Reflective Total Nasal Symptom Score
RT-PCR,reverse transcriptase polymerase chain reaction
RXR?,retinoid X                                     receptor subtypes
RXRs,retinoid X receptors
RXRs,retinoid X                             receptors
S. faecalis,strains of the following organisms:  Escherichia coli     Enterococcus
S. pyogenes,Streptococcus pyogenes
S. pyogenes,older.Streptococcus pyogenes
s.c.,Subcutaneous
s.c.,subcutaneously
S/D,solvent/detergent
SAD,Social Anxiety Disorder
SAD,1.1)Social Anxiety Disorder
SAE,serious adverse event
SAEs,Serious adverse events
SAEs,serious AEs
SAH,subarachnoid hemorrhage
SAM,S-adenosylmethionine
SAMHSA,Substance Abuse and Mental Health Services Administration
SAMHSA,Substance Abuse and Mental Health  Services Administration
SANS,Scale for Assessing Negative Symptoms
SAP,serum alkaline phosphatase
SAR,seasonal allergic rhinitis
SARs,serious adverse reactions
SAT,subcutaneous adipose tissue
SAVE,Survival and Ventricular Enlargement
sBCC,superficial basal cell carcinoma
SBECD,sulfobutylether ?-cyclodextrin sodium
SBIAB,secondary bacterial infections of acute bronchitis
SBP,systolic blood pressure
SBR,staying on the baseline antiretroviral regimen
SC,subcutaneous injection
sc,StimulantStimulant DoseCimetidine% InhibitionBetazole1.5 mg/kg
SC,Subcutaneous
SC,subcutaneously
SCAG,Sandoz-Clinical Assessment Geriatric
SCCHN,squamous cell carcinoma of the head and neck
SCE,sister chromatid exchange
SCE,sister chromatid exchanges
SCEs,sister chromatid exchanges
SCL,sinus cycle length
SCLC,small cell lung cancer
SCN,Severe chronic neutropenia
Scores,scores of nasal and non-nasal symptoms
Scr,serum creatinine concentrations
Scr,serum creatinine
SCT,symbol copying test
SD,standard  deviation
SD,subjects resulted in mean
SD,sensory penetration depth
SD,standard deviation
SD,"styleCode=""bold"">Mean"
SD,simulated mean
SD,"styleCode=""bold"">Baseline  <br/>Mean"
SD,"styleCode=""bold"">Week 4  <br/>Mean"
SD,"styleCode=""bold"">Week 12  <br/>Mean"
SD,systolic blood pressure [mean
SDA,single dermal administration
S-DCT,S-demethylcitalopram
SDD,Susceptible-Dose Dependent
S-DDCT,S-didemethylcitalopram
SDFS,systemic disease-free survival
SDS,Symptom Distress Scale
SDS,Sheehan Disability Scale
SDS,standard deviation  score
SDS,Standard Deviation Score
SE,Serum Calcium
seasonal,study to evaluate differences in Lazanda absorption in individuals with induced allergic
Sedation:,See WARNINGS and DOSAGE AND ADMINISTRATION - Handling Procedures.
SeDBP,seated diastolic blood pressure
see,suicide among untreated patients
see,serious hepatotoxicity
see,serum sickness
see,should be monitored frequently
see,sustained fever
see,seizure
see,should be considered
see,seek immediate medical therapy
see,signs of renal failure
see,seek immediate emergency help
see,systematically investigated
see,serotonin syndrome
see,supplements is not recommended
see,substantially altered in the elderly
see,sodium are recommended for elderly patients
see,signs of renal insufficiency  or failure
see,Seizure Threshold:                            WARNINGS
see,should not be exceeded
see above,significantly different from the bioavailability of amlodipine and atorvastatin  administered separately
see and,serum theophylline concentrations are required in pediatric patients
see and,Safety and effectiveness in the pediatric population have not been established
see Table,species of meclofenamic acid and Metabolite I
selenium,Selenium metallicum
SER,spontaneous epileptic rat
SeSBP,seated systolic blood pressure
Sevo/N2O/O2,sevoflurane-N2O/O2
Sevo/O2,sevoflurane-O2
SF-36,Short Form-36
SF-36,Short Form 36
SFR,stenosis flow reserve
SGA,small for gestational age
SGA,small  for gestational age
SGOT,significant  increase was observed in median AST
SGOT,significant increase was observed in median AST
SGOT,serum glutamic oxaloacetic transaminase
SGOT,serum glutamate oxaloacetic transaminase
SGOT,serum glutamic-oxalacetic transaminase
SGOT,Significant elevations of aminotransferase AST
SGOT,serum glutamic oxalacetic transaminase
SGOT,serum glutamic-oxaloacetic transaminase
SGPT,serum glutamate pyruvate transaminase
SH,sulfhydryl
SHARP,Study of Heart and Renal Protection
SHBG,sex hormone binding globulin
SHBG,sex hormone-binding globulin
SHBG,sex hormone  binding globulin
SHBG,sex hormone?binding globulin
SHBG,sex-hormone-binding globulin
SHBG,sex hormone-binding  globulin
SHBG,sex hormone binding  globulin
sHS,synthetic human secretin
SIADH,syndrome of inappropriate antidiuretic hormone secretion
SIADH,syndrome of inappropriate antidiuretic hormone
SIADH,syndrome of inappropriate ADH secretion
SIADH,mellitus
SIADH,syndrome of  inappropriate antidiuretic hormone
SIADH,syndrome of inappropriate antidiuretic                                     hormone secretion
SIADH,syndrome of inappropriate  antidiuretic hormone secretion
SIADH,syndrome of inappropriate antidiuretic hormone  secretion
SIADH,syndrome of inappropriate antidiureic hormone secretion
SIB,Severe Impairment Battery
SIB,Severe  Impairment Battery
SiDBP,sitting diastolic blood pressure
SIDS,Sudden Infant Death Syndrome
SIR,systemic inflammatory response
SJIA,Systemic Juvenile Idiopathic Arthritis
SJS,Stevens-Johnson syndrome
SJS, Stevens-Johnson Syndrome
SLE,Systemic lupus erythematosus
sleep aids,should not combine meperidine hydrochloride tablets with alcohol or other central nervous system depressants
SM,systemic mastocytosis
SMAP,2–sulfamoylacetyl phenol
SMAP,2-sulfamoylacetyl phenol
SNP,sodium nitroprusside
SNRI,serotonin and norepinephrine reuptake inhibitor
SNRIs,serotonin norepinephrine reuptake inhibitors
SNRIs,serotonin and norepinephrine reuptake inhibitors
SNRIs,serotonin and  norepinephrine reuptake inhibitors
SNRIs,Serotonin and Norepinephrine Reuptake  Inhibitors
SNRIs,serotonin norepinephrine reuptake  inhibitors
SNRIs,serotonin norepinephrine  reuptake inhibitors
SNRIs,serotonin and norepinephrine reuptake  inhibitors
SOC,System Organ Class
SOC,System Order Class
SOCA,Studies of the Ocular Complications of AIDS
SODAS®,Spheroidal Oral  Drug Absorption System
SODAS®,Spheroidal Oral Drug Absorption System
sodium,should be avoided.Serum electrolytes
Sodium,sodium
Sodium®,Sodium Capsules
Solution,solution
SPARCL,Stroke Prevention by Aggressive Reduction in Cholesterol Levels
SPARCL,Stroke Prevention by Aggressive Reduction in  Cholesterol Levels
SPECT,Single photon emission computed tomography
sPGA,Static Physician Global Assessment
SPID,sum of pain intensity  difference
SPID,sum of pain intensity difference
SPID,Summed Pain Intensity Differences scale
SPID30,sum of pain intensity difference at 30 minutes
SPID30,sum of the pain intensity difference at 30 minutes
SPID48,sum of pain intensity difference over  the first 48 hours
Spray,sprays/nostril twice daily
sPS,synthetic porcine secretin
SR,sustained response
SR,(SR)
SR,sustained-release tablets
SR®,(SR)
SR®*,(SR)
Sr-82,STRONTIUM-82
Sr-85,STRONTIUM-85
SREs,skeletal-related events
SRP,scaling and root planing
SRS-A,slow-reacting substance of anaphylaxis
SS,serotonin syndrome
SS,sulfur USP 5%
SSA,standard sedative agents
SSD,PAH/Scleroderma Spectrum of Diseases
SSRI,selective serotonin reuptake inhibitor-
SSRI,selective serotonin reuptake inhibitor
SSRI,selective  serotonin reuptake inhibitor
SSRI-,selective serotonin reuptake inhibitor-
SSRIs,selective serotonin reuptake inhibitors
SSRIs,selective serotonin  reuptake inhibitors
SSRIs,Selective  Serotonin Reuptake Inhibitors
SSRIs,Selective  Serotonin Reuptake Inhibitors<br/>&#160;
SSRIs,selective serotonin reuptake  inhibitors
SSRIs,selective serotonin re-uptake inhibitors
SSRI's,selective serotonin reuptake inhibitors
SSTR,somatostatin receptors
SSV,Suspension Structured Vehicle USP-NF
STA,soft-tissue anesthesia
STA,Sequential Treatments  Analysis
STA,Sequential Treatments Analysis
stage 1,study was designed to evaluate the effect of 10 mg vardenafil
Stage IA-IIA,Studies Targretin® gel was evaluated for the                                     treatment of patients with early stage
Statins,STABILIZED.HMG-CoA Reductase Inhibitors
STEARATE,stearate
STEC-HUS,Shiga toxin E. coli related hemolytic uremic syndrome
STEMI,ST-segment elevation myocardial infarction
STEMI,ST-elevation myocardial infarction
Steri-Dose,solution containing 50 mg diphenhydramine hydrochloride in a 1-mL disposable syringe
STH,somatotropic hormone
Study 1,study of 212 patients
study 2,Rate      STUDY 2 Maximum Flow RateIn one fixed dose study
SU,sulfonylurea drugs
SUDEP,Sudden Unexplained Death in Epilepsy
SUFENTA,Sufentanil Citrate Injection
supine,Subcutaneous Injection Technique: Patients should be lying down
supine,injection.Subcutaneous Injection Technique: Patients should be lying down
SUSPENSION,suspension
SVR,systemic vascular resistance
SVR,Sustained Virologic Response
SVT,supraventricular tachycardia
SVT,supraventricular
S-warfarin,single dose of warfarin sodium on the fifth day
S-warfarin,single dose of  warfarin sodium on the fifth day
SWD,Shift Work Sleep Disorder
SWFI,
SWOG,Southwest Oncology Group
SWOG,Southwestern Oncology Group
Syndrome,Syndromeand PRECAUTIONS: Information for the Patients
T½?,the nitroglycerin
T2DM,type 2 diabetes mellitus
TA,triamterene
TAAEs,temporally associated adverse events
Table 3,the laboratory abnormalities described for Study 934
Tablets,tablets
T-ALL,T-cell acute lymphoblastic leukemia
TAMs,Thymidine analogue mutations
TBG,thyroxine-binding globulin
TBG,thyroxine-binding  globulin
TBg,thyroid-binding globulin
TBG,thyroid  binding globulin
TBG,thyroid binding globulin
TBI,total-body irradiation
TBPA,thyroxine-binding  prealbumin
TBPA,thyroxine-binding prealbumin
TBPA,thyroid-binding prealbumin
TBPS,t-butyl-bicyclophosphorothionate
TBR,to breast cancer recurrence
TC,total cholesterol
TCA,tricyclic antidepressant
TCAs,tricyclic antidepressants
TCAs,tricyclic  antidepressants
TCAs,reduced.Tricyclic Antidepressants
TCAs,.Tricyclic Antidepressants
TCN,tetracycline hydrochloride
TDD,total daily  dose
TDM,to distant metastasis
TDM,therapeutic drug monitoring
TdP,torsades de pointes
TE,thromboembolic
TEAE,treatment-emergent adverse events
TEAEs,treatment-emergent adverse event
teaspoon,the capsule and sprinkling the entire contents on a small amount
TEN,toxic epidermal necrolysis
TEN,
TEN, Toxic epidermal necrolysis
TEN,TOXIC EPIDERMAL  NECROLYSIS
TERIS,Teratogenic effects of drugs: a resource for                 clinicians
TERIS,Teratogen Information System
TERIS,there is no risk
TERIS,there is no  risk
test,the uneventful administration of the initial 1 mL
test,treated with Trasylol® should first receive an initial
TFMA,4-trifluoromethylaniline
TFMA,trifluoromethylaniline
TFR,tumor flare reaction
TG,triglycerides
TG,triglyceride
that is,three inhalations of Alupent
that is,the renin-angiotensin system
THC,tetrahydrocannabinol
thiamine,Thiamine Mononitrate
thiazide,The diuretic effects of chlorthalidone and the benzothiadiazine
TIA,transient ischemic attack
TIA,stroke/transient ischemic attack
TIBC,total iron binding capacity
TID,three divided doses
TID,times daily
TIMOPTIC,timolol maleate ophthalmic solution
TIRF,Transmucosal Immediate Release Fentanyl
TIV,Trivalent Inactivated Influenza Vaccine
tiw,times a week
TIW,times per week
TIX,tixocortol-21-pivalate
tizanidine,Tizanidine HCl
tizanidine,Tizanidine hydrochloride
TK,thymidine kinase
T-LBL,/T-cell lymphoblastic lymphoma
T-LBL,T-cell lymphoblastic lymphoma
TLC,thin-layer chromatography
TLS,tumor lysis syndrome
TMA,thrombotic micro-angiopathy
TMA,thrombotic microangiopathy
Tmax,to maximum concentration
tmax,to reach maximum concentration
Tmax,to maximum plasma concentration
Tmax,to maximum  concentration
Tmax,time of maximum plasma concentration
Tmax,to reach maximum plasma concentration
Tmax,to maximum plasma concentration of cefprozil
Tmax,time to peak exposure
Tmax,the maximum concentration in serum
tmax,time of maximum concentration
Tmax,time of maximum  plasma concentration
Tmax,to Cmax
Tmax,to maximal naproxen levels
Tmax,to reach maximum verapamil concentrations
Tmax,to reach Cmax
Tmax,to maximum plasma  concentrations
TMP/SMX,trimethoprim/sulfamethoxazole
TMP/SMX,trimethoprim?sulfamethoxazole
TMS,"styleCode=""italics"">&#945;</content>-(thiomethyl) spirolactone"
TMS,&#945;-(thiomethyl)<br/>spironolactone
TMTX/LV,trial comparing Neutrexin with concurrent leucovorin protection
TN,true negative
TNAs,total nutrient admixtures
TNBP,tri-n-butyl phosphate
TNSS,total nasal symptom scores
TNT,to New Targets Study
TNT,to Occurrence of Major Cardiovascular Events
TOC,test-of-cure
TOF,train-of-four
top/bottom,"<td styleCode=""Botrule Lrule Rrule""> Caplet </td>                         </tr>                         <tr>                            <td styleCode=""Botrule Lrule Rrule"">                               <content styleCode=""bold"">Debossment"
topical,acidsulindaccisapridemethimazole*tamoxifenclarithromycinmethyldopatetracyclineclofibratemethylphenidatethyroidwarfarin sodium overdosemethylsalicylate ointment
topiramate,to 4250 mg DivalproexSodium Delayed-Release TabletsConcomitant antiepilepsy drugs
topiramate,TOPAMAX® in the acute treatment of migraine headache has not been studied.®
TOPO IV,topoisomerase IV
torsade,torsades
total,the risk of death or hospitalization
total,the combined end points of all-cause mortality plus hospitalization
total dose,total daily doses should not exceed 2 sprays in each nostril
Total-C,total cholesterol
total-C,total  cholesterol
TP,true positive
T-P,to placebo
t-PA,7.3)Tissue-type plasminogen activator
t-PA,tissue-type plasminogen activator
t-PA,hydrochloride*ticlopidinediazoxidenalidixic acidtissue plasminogen activator
t-PA,tissue plasminogendiclofenacmoricizine hydrochlorideactivator
TPMT,thiopurine S-methyltransferase
TPN,total parenteral nutrition
TPN,Total Parenteral     Nutrition
TPN,desired.Total parenteral nutrition
TPV,Tipranavir
Trade,"<tr><td valign=""bottom""><content styleCode=""bold"">Nonproprietary"
TRALI,Transfusion Related Acute Lung Injury
TRALI,Transfusion-Related Acute Lung Injury
Treatment,treatment and are represented above
TRF,thyroid release factor
TRF,thyroid releasing factor
TRH,Thyrotropin-releasing hormone
TRH,thyrotropin releasing hormone
Trial,Treated With Carvedilol
Trials,trials
Trials 1,Trials:                   Among 1554 patients treated with FROVA in four placebo-controlled  trials
triazole,Three metabolites of  anastrozole
triazole,Three metabolites of anastrozole
triptan,treatment of fluoxetine with a 5-hydroxytryptamine receptor  agonist
TRNG,tetracycline-resistant Neisseria gonorrhoeae
TRNG,tetracycline-resistant Neisseria gonorrhoae
TRNG,tetracycline-resistant Neisseria                             gonorrhoeae
TROVAN,trovafloxacin mesylate
TS,Turner syndrome
TSE,transmissible spongiform encephalopathy
TSH,thyrotropin stimulating  hormone
TSH,thyrotropin stimulating hormone
TSH,thyroid stimulating hormone
TSH,thyroid-stimulating hormone
TSH,Thyroid stimulating  hormone
TSH,Thyrotropin-Stimulating Hormone
TSO,to sleep onset
TSO,to  sleep onset
TSS,toxic shock syndrome
TSS,TOTAL SYMPTOM SCORE
TSS,Total Sharp Score
TT,thrombin time
T-T,to tesamorelin
TTP,thrombocytopenic purpura
TTP,time to progression
TTP,Time to  progression
TTP,<br/>Time to progression
TTP/HUS,thrombocytopenic purpura/hemolytic uremic syndrome
TUR,transurethral resection
TURB,transurethral resection of the bladder
TURP,transurethral resection of the prostate
TVU,transvaginal ultrasonography
TZD,thiazolidinedione
U.S.,United States
U.V.,ultraviolet
U/L,upper limit of normal
UA,[unstable angina
UCD,urea cycle disorder
UCD,WARNINGS-Urea Cycle Disorders
UDS,unscheduled DNA synthesis
UDS,unscheduled  DNA synthesis
UDS,unscheduled DNA syntheses
UFH,unfractionated heparin
UGDP,University Group Diabetes Program
UGT,UDP-glucuronosyltransferase
UGT1A1,UDP-glucuronosyl transferase 1A1
UICC,Union Internationale Contre le Cancer
ULN,upper limit of normal
UPDRS,Unified Parkinson’s Disease Rating Scale
UPDRS,Unified Parkinson's Disease Rating Scale
URI,Upper Respiratory Tract Infection
URI,upper respiratory infection
USA,use.Caution: Federal
Use,USE IN NEWBORNS.
Use,USAGE andDOSAGE AND ADMINISTRATION.
Use,USAGE and DOSAGE AND ADMINISTRATION.
Use:,USE IN NEWBORNS.
USP,United States Pharmacopeia
UTIs,urinary tract infections
UV,ultraviolet light
UV,ultraviolet
V/F,Volume of Distribution
V/F,Volume of<br/>Distribution
V?,volume
VaD,vascular dementia
VaD,vascular  dementia
VALIANT,Valsartan in Acute Myocardial Infarction Trial
VAS,visual analog scale
VAS,Visual Analog Score
VAS,visual analog scores
VASPI,Visual Analog Scale of Pain Intensity
VAT,visceral adipose tissue
Vc,volumes of distribution centrally
vCJD,variant Creutzfeldt-Jakob disease
Vd,volume of distribution
Vd,ss
Vd?,volume of distribution
vdH-S,van der Heijde-Sharp
Vdss,volume of distribution at steady state
VF,ventricular fibrillation
VGCV,valganciclovir
Vial,"valign=""top""/></tr> <tr><td valign=""top""><paragraph>Temperature Probe"
Vial,vial
VKA,vitamin-K  antagonist
VKA,vitamin-K antagonist
VKOR,vitamin K epoxide reductase
VLDL,very low density lipoprotein
VLDL,very-low-density  lipoprotein
VLDL,very low-density lipoprotein
VLDL,very-low-density lipoproteins
VLDL,very low density lipoprotine
VLDL,very low  density lipoprotein
VLDLs,very low density lipoproteins
VMA,vanillylmandelic acid
VOD,veno-occlusive disease
Vomiting,Vomiting.
VRS,Verbal Rating Scale
Vss,volume of distribution at steady state
Vss,volume of  distribution at steady state
Vss,volume of distribution at steady-state
VSV,vesicular stomatitis virus
VT,ventricular tachycardia
VT,ventricular
VTE,venous thromboembolic
VTE,venous thromboembolism
VWD,von Willebrand disease
VWD,1.2
vWF,Von Willebrand factor
VZV,varicella zoster virus
VZV,varicella-zoster virus
WARIS,Warfarin Re-Infarction Study
WASO,wake time after sleep onset
water,water.Prepare an aqueous
WBC,white blood cell
WBC,white blood cell count
WG,Wegener's Granulomatosis
WHI,Women’s Health Initiative
WHI,Women's Health Initiative
WHI,Women&#8217;s Health Initiative
WHI,Women's Health  Initiative
WHI,Women’s Health  Initiative
WHIMS,Women’s Health Initiative Memory Study
WHIMS,WHI Memory Study
WHIMS,Women's Health Initiative Memory Study
WHIMS,WHI  Memory Study
WHIMS,Women&#8217;s Health Initiative Memory Study
WHIMS,Women’s Health  Initiative Memory Study
WHO,World Health Organization
WHO,World  Health Organization
WHO PS,WHO performance status
WNV,West Nile virus
Wort,WARNINGS:  Serotonin Syndrome or Neuroleptic Malignant Syndrome (NMS
WPW,Wolf Parkinson’s White
WPW,Wolff-Parkinson-White
WPW,Wolff-Parkinson-White syndrome
XO,xanthine oxidase
Y-90-,Yttrium-90-
YBOCS,Yale Brown Obsessive Compulsive Scale
YBOCS,Yale–Brown Obsessive-Compulsive Scale
YBOCS,Yale-Brown Obsessive Compulsive Scale
Y-BOCS,Yale-Brown Obsessive Compulsive Scale
YGTSS,Yale Global Tic Severity Scale Total Score
YMRS,Young Mania Rating Scale
Y-MRS,Young Mania Rating Scale
Y-MRS,Young Mania  Rating Scale
ZDV,zidovudine
ZDV-TP,zidovudine triphosphate
ZE,Zollinger-Ellison
ZES,Zollinger-Ellison syndrome
Zinc,zinc oxide
